

Peter Mac publications 2019

January 2019

1. Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, Thijssen R, Yeh P, Wong SQ, Ftouni S, Lam EYN, Anderson MA, Pott C, Gilan O, Bell CC, Knezevic K, Blombery P, Rayeroux K, Zordan A, Li J, Huang DCS, Wall M, Seymour JF, Gray DHD, Roberts AW, Dawson MA, Dawson SJ. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. *Nature Medicine* 2019;25:119-29.
2. Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature. *European Journal of Nuclear Medicine and Molecular Imaging* 2019;46:238-50.
3. Aits S. Methods to Detect Loss of Lysosomal Membrane Integrity. *Methods in Molecular Biology* 2019;1880:315-29.
4. Alexander M, Ball D, Solomon B, MacManus M, Manser R, Riedel B, Westerman D, Evans SM, Wolfe R, Burbury K. Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer. *Cancers* 2019;11:50.
5. Alexiadis M, Rowley SM, Chu S, Leung DTH, Stewart CJR, Amarasinghe KC, Campbell IG, Fuller PJ. Mutational Landscape of Ovarian Adult Granulosa Cell Tumors from Whole Exome and Targeted TERT Promoter Sequencing. *Molecular Cancer Research* 2019;17:177-85.
6. Annunziato S, de Ruiter JR, Henneman L, Brambillasca CS, Lutz C, Vaillant F, Ferrante F, Drenth AP, van der Burg E, Siteur B, van Gerwen B, de Bruijn R, van Miltenburg MH, Huijbers IJ, van de Ven M, Visvader JE, Lindeman GJ, Wessels LFA, Jonkers J. Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer. *Nature Communications* 2019;10:397.
7. Atkins L, Steer B, Ray H, Kiss N. Implementing and sustaining an evidence-based nutrition service in a haematology unit for autologous stem cell transplant patients. *Supportive Care in Cancer* 2019;27:951-8.
8. Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Hoppe RT, Mikhaeel NG. Definitive radiotherapy for localized follicular lymphoma staged by ¹⁸F-FDG PET-CT: a collaborative study by ILROG. *Blood* 2019;133:237-45.
9. Britton B, Baker AL, Wolfenden L, Wratten C, Bauer J, Beck AK, McCarter K, Harrowfield J, Isenring E, Tang C, Oldmeadow C, Carter G. Eating As Treatment (EAT): A Stepped-Wedge, Randomized Controlled Trial of a Health Behavior Change Intervention Provided by Dietitians to Improve Nutrition in Patients With Head and Neck Cancer Undergoing Radiation Therapy (TROG 12.03). *International Journal of Radiation Oncology, Biology, Physics* 2019;103:353-62.
10. Brown NJ, Bhatia K, Teague J, White SM, Lo P, Challis J, Beshay V, Sullivan M, Malkin D, Hansford JR. Report of a bi-allelic truncating germline mutation in TP53. *Familial Cancer* 2019;18:101-4.
11. Cahill V, Sinclair B, Malpas CB, McIntosh AM, Chen Z, Vivash LE, O'Shea MF, Wilson SJ, Desmond PM, Berlangieri SU, Hicks RJ, Rowe CC, Morokoff AP, King JA, Fabinyi GC, Kaye AH, Kwan P, Berkovic SF, O'Brien TJ. Metabolic patterns and seizure outcomes following anterior temporal lobectomy. *Annals of Neurology* 2019;85:241-50.
12. Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. *Blood* 2019;133:299-305.

13. Chiong E, Murphy DG, Akaza H, Buchan NC, Chung BH, Kanesvaran R, Khochikar M, Letran J, Lojanapiwat B, Ng CF, Ong T, Pu YS, Saad M, Schubach K, Turkeri L, Umbas R, Le Chuyen V, Williams S, Ye DW, Davis ID. Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017. *BJU International* 2019;123:22-34.
14. Coffman LG, Pearson AT, Frisbie LG, Freeman Z, Christie E, Bowtell DD, Buckanovich RJ. Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma. *Stem Cells* 2019;37:257-69.
15. Dendle C, Gan PY, Polkinghorne KR, Ngui J, Stuart RL, Kanellis J, Thursky K, Mulley WR, Holdsworth S. Natural killer cell function predicts severe infection in kidney transplant recipients. *American Journal of Transplantation* 2019;19:166-77.
16. Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. *Lancet Oncology* 2019;20:267-81.
17. Diesch J, Bywater MJ, Sanij E, Cameron DP, Schierding W, Brajanovski N, Son J, Sornkom J, Hein N, Evers M, Pearson RB, McArthur GA, Ganley ARD, O'Sullivan JM, Hannan RD, Poortinga G. Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation. *Communications Biology* 2019;2:39.
18. Douglas AP, Atarod M, Prince HM. FDG-PET/CT findings, the vital clue to rare diagnosis of herpes simplex virus lymphadenitis simulating Richter transformation. *Pathology* 2019;51:102-4.
19. Douglas AP, Thursky KA, Worth LJ, Drummond E, Hogg A, Hicks RJ, Slavin MA. FDG PET/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging. *Eur J Nucl Med Mol Imaging*. 2019;46:166-173.
20. Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L, Epstein R, Blanksby A, Horvath L, Guminski A, Mahon K, Gedye C, Yin C, Stricker P, Joshua AM. Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. *Clinical Genitourinary Cancer* 2019;17:15-22.
21. Fleming CL, Natoli A, Schreuders J, Devlin M, Yoganantharajah P, Gibert Y, Leslie KG, New EJ, Ashton TD, Pfeffer FM. Highly fluorescent and HDAC6 selective scriptaid analogues. *European Journal of Medicinal Chemistry* 2019;162:321-33.
22. Granger CL, Parry SM, Edbrooke L, Abo S, Leggett N, Dwyer M, Denehy L. Improving the delivery of physical activity services in lung cancer: A qualitative representation of the patient's perspective. *European Journal of Cancer Care* 2019;28:e12946.
23. Gustafsson UO, Scott MJ, Hubner M, Nygren J, Demartines N, Francis N, Rockall TA, Young-Fadok TM, Hill AG, Soop M, de Boer HD, Urman RD, Chang GJ, Fichera A, Kessler H, Grass F, Whang EE, Fawcett WJ, Carli F, Lobo DN, Rollins KE, Balfour A, Baldini G, Riedel B, Ljungqvist O. Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations: 2018. *World Journal of Surgery* 2019;43:659-95.
24. Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Kong DCM, Chen SC. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. *Clinical Microbiology and Infection* 2019;25:26-34.
25. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesueur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun

BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI, Bickeboller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnstrom H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldes T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collee JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dork T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, Garcia-Saenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guenel P, Hakansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Hogdall E, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kuhl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeny LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowitz F, Lenz HJ, Leslie G, Lessel D, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Loupakis F, Lubinski J, Maehle L, Maier C, Mannermaa A, Marchand LL, Margolin S, May T, McGuffog L, Meindl A, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, Mucci L, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olama AAA, Olopade OI, Olshan AF, Olsson H, Osorio A, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennert G, Rennert HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, De Ruyck K, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slattey ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sundfeldt K, Sutphen R, Swerdlow AJ, Tajara EH, Tangen CM, Tardon A, Taylor JA, Teare MD, Teixeira MR, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Bjorge L, Tischkowitz M, Toland AE, Torres D, Townsend PA, Travis RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Vega A, Aguado-Barrera ME, Wang Q, Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, Wichmann HE, Wiklund F, Winqvist R, Wolk A, Woll P, Woods M, Wu AH, Wu X, Yannoukakos D, Zheng W, Zienolddiny S, Ziogas A, Zorn KK, Lane JM, Saxena R, Thomas D, Hung RJ, Diergaarde B, McKay J, Peters U, Hsu L, Garcia-Closas M, Eeles RA, Chenevix-Trench G, Brennan PJ, Haiman CA, Simard J, Easton DF, Gruber SB, Pharoah PDP, Price AL, Pasaniuc B, Amos CI, Kraft P, Lindstrom S. Shared heritability and functional enrichment across six solid cancers. *Nature Communications* 2019;10:431.

26. Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. *Journal of Clinical Oncology* 2019;37:269-77.
27. Khor RC, Nguyen A, O'Dwyer J, Kothari G, Sia J, Chang D, Ng SP, Duchesne GM, Foroudi F. Extracting tumour prognostic factors from a diverse electronic record dataset in genito-urinary oncology. *International Journal of Medical Informatics* 2019;121:53-7.
28. Kinnear N, O'Callaghan M, Hennessey D, Liddell H, Newell B, Bolt J, Lawrentschuk N. Intra-operative cell salvage in urological surgery: a systematic review and meta-analysis of comparative studies. *BJU International* 2019;123:210-9.
29. Kiss N, Gilliland S, Quinn P, Atkins L, Black J, Frowen J. Evaluating the effectiveness of a nutrition assistant role in a head and neck cancer clinic. *Nutrition & Dietetics* 2019;76:21-7.

30. Kok M, Winer EP, Loi S. Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study. *Annals of Oncology* 2019;30:13-6.
31. Kutasovic JR, McCart Reed AE, Males R, Sim S, Saunus JM, Dalley A, McEvoy CR, Dedina L, Miller G, Peyton S, Reid L, Lal S, Niland C, Ferguson K, Fellowes AP, Al-Ejeh F, Lakhani SR, Cummings MC, Simpson PT. Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study. *Journal of Pathology Clinical Research* 2019;5:25-39.
32. Lancia A, Zilli T, Achard V, Dirix P, Everaerts W, Gomez-Iturriaga A, Ingrosso G, Liefhooghe N, Miralbell R, Siva S, Van der Eecken K, Ost P. Oligometastatic prostate cancer: The game is afoot. *Cancer Treatment Reviews* 2019;73:84-90.
33. Lattimore VL, Pearson JF, Morley-Bunker AE, Investigators K, Spurdle AB, Robinson BA, Currie MJ, Walker LC. Quantifying BRCA1 and BRCA2 mRNA Isoform Expression Levels in Single Cells. *International Journal of Molecular Sciences* 2019;20:693.
34. Lawrentschuk N. Editorial Comment. *Journal of Urology* 2019;201:68-9.
35. Le Roux PY, Hicks RJ, Siva S, Hofman MS. PET/CT Lung Ventilation and Perfusion Scanning using Galligas and Gallium-68-MAA. *Seminars in Nuclear Medicine* 2019;49:71-81.
36. Lee CHA, Kong JCH, Heriot AG, Warriar S, Zalcborg J, Sitzler P. Short-term outcome of emergency colorectal cancer surgery: results from Bi-National Colorectal Cancer Audit. *International Journal of Colorectal Disease* 2019;34:63-9.
37. Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. *British Journal of Cancer* 2019;120:279-85.
38. Lelliott EJ, Cullinane C, Martin CA, Walker R, Ramsbottom KM, Souza-Fonseca-Guimaraes F, Abuhammad S, Michie J, Kirby L, Young RJ, Slater A, Lau P, Meeth K, Oliaro J, Haynes N, McArthur GA, Sheppard KE. A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. *Scientific Reports* 2019;9:1225.
39. Loh Z, Yeo B, Williams DS, Gyorki DE. Ectopic breast cancer in the inguinal region. *Breast Journal* 2019;25:155-6.
40. Ma X, Zhang L, Song J, Nguyen E, Lee RS, Rodgers SJ, Li F, Huang C, Schittenhelm RB, Chan H, Chheang C, Wu J, Brown KK, Mitchell CA, Simpson KJ, Daly RJ. Characterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation. *Nature Commun.* 2019;10:296.
41. MacManus M, Fisher R, McClure B, Seymour JF. Reply to M. Sorigue et al. *Journal of Clinical Oncology* 2019;37:257-8.
42. Maleki S, Alexander M, Fua T, Liu C, Rischin D, Lingaratnam S. A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies. *Journal of Oncology Pharmacy Practice* 2019;25:130-9.
43. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomaki K, Allen J, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Auer PL, Auvinen P, Barrdahl M, Beane Freeman LE, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Borresen-Dale AL, Brauch H, Bremer M, Brenner H, Brentnall A, Brock IW, Brooks-Wilson A, Brucker SY, Bruning T, Burwinkel B, Campa D, Carter BD, Castelao JE, Chanock SJ, Chlebowski R, Christiansen H, Clarke CL, Collee JM, Cordina-Duverger E, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dork T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Forsti A, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, Garcia-Saenz JA, Gaudet MM, Georgoulas V, Giles GG, Gilyazova IR, Glendon G, Goldberg MS, Goldgar DE, Gonzalez-Neira A, Grenaker Alnaes GI, Grip M, Gronwald J, Grundy A, Guenel P, Haeberle L, Hahnen E, Haiman CA, Hakansson N, Hamann U,

Hankinson SE, Harkness EF, Hart SN, He W, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Jakimovska M, Jakubowska A, Janni W, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kaczmarek K, Kataja V, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Knight JA, Ko YD, Kosma VM, Koutros S, Kristensen VN, Kruger U, Kuhl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowitz F, Lilyquist J, Lindblom A, Lindstrom S, Lissowska J, Lo WY, Loibl S, Long J, Lubinski J, Lux MP, MacInnis RJ, Maishman T, Makalic E, Maleva Kostovska I, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Martinez ME, Mavroudis D, McLean C, Meindl A, Menon U, Middha P, Miller N, Moreno F, Mulligan AM, Mulot C, Munoz-Garzon VM, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen SF, Nordestgaard BG, Norman A, Offit K, Olson JE, Olsson H, Orr N, Pankratz VS, Park-Simon TW, Perez JIA, Perez-Barrios C, Peterlongo P, Peto J, Pinchev M, Plaseska-Karanfilska D, Polley EC, Prentice R, Presneau N, Prokofyeva D, Purrington K, Pylkas K, Rack B, Radice P, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Robson M, Romero A, Ruddy KJ, Ruebner M, Saloustros E, Sandler DP, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schurmann P, Schwentner L, Scott C, Scott RJ, Seynaeve C, Shah M, Sherman ME, Shrubsole MJ, Shu XO, Slager S, Smeets A, Sohn C, Soucy P, Southey MC, Spinelli JJ, Stegmaier C, Stone J, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Thone K, Tollenaar R, Tomlinson I, Truong T, Tzardi M, Ulmer HU, Untch M, Vachon CM, van Veen EM, Vijai J, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Yang XR, Yannoukakos D, Zhang Y, Zheng W, Ziogas A, Dunning AM, Thompson DJ, Chenevix-Trench G, Chang-Claude J, Schmidt MK, Hall P, Milne RL, Pharoah PDP, Antoniou AC, Chatterjee N, Kraft P, Garcia-Closas M, Simard J, Easton DF. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *American Journal of Human Genetics* 2019;104:21-34.

44. McCart Reed AE, Kalaw E, Nones K, Bettington M, Lim M, Bennett J, Johnstone K, Kutasovic JR, Saunus JM, Kazakoff S, Xu Q, Wood S, Holmes O, Leonard C, Reid LE, Black D, Niland C, Ferguson K, Gresshoff I, Raghavendra A, Harvey K, Cooper C, Liu C, Kalinowski L, Reid AS, Davidson M, Pearson JV, Pathmanathan N, Tse G, Papadimos D, Pathmanathan R, Harris G, Yamaguchi R, Tan PH, Fox SB, O'Toole SA, Simpson PT, Waddell N, Lakhani SR. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications. *Journal of Pathology* 2019;247:214-27.
45. McDowell L, Corry J. Radiation therapy quality assurance in head and neck radiotherapy - Moving forward. *Oral Oncology* 2019;88:180-5.
46. Michie J, Beavis PA, Freeman AJ, Vervoort SJ, Ramsbottom KM, Narasimhan V, Lelliott EJ, Lalaoui N, Ramsay RG, Johnstone RW, Silke J, Darcy PK, Voskoboinik I, Kearney CJ, Oliaro J. Antagonism of IAPs Enhances CAR T-cell Efficacy. *Cancer Immunology Research* 2019;7:183-92.
47. Murphy CE, Walker AK, Shannon Weickert C. Where There's Smoke, There's Fire-But Who Is Lighting the Match? Bolstering Transcriptional Evidence for the Role of Nuclear Factor-kappaB in Neuroimmune Activation in Schizophrenia. *Biological Psychiatry* 2019;85:5-7.
48. Ng SP, Khor R, Bressel M, MacManus M, Seymour JF, Hicks RJ, Wirth A. Outcome of patients with early-stage follicular lymphoma staged with ¹⁸F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone. *European Journal of Nuclear Medicine and Molecular Imaging* 2019;46:80-6.
49. Ngan D, Chu J, Chander S, Michael M, Heriot AG, Ngan SY, Rischin D, Leong T. A clinical trial with protracted infusion 5-fluorouracil and mitomycin C for localized squamous cell carcinoma of the anus. *Asia Pacific Journal of Clinical Oncology* 2019;15:75-81.
50. Ong WL, Foroudi F, Evans S, Millar J. Androgen deprivation therapy use with post-prostatectomy radiotherapy in the Prostate Cancer Outcomes Registry Victoria. *Journal of Medical Imaging and Radiation Oncology* 2019;63:124-30.
51. Pascoe C, Christidis D, Manning TG, Lamb BW, Murphy DG, Lawrentschuk N. Photoselective Vaporization of the Bladder for the Management of Radiation Cystitis-Technique and Initial Outcomes. *Urology* 2019;123:295.

52. Pattison DA, MacFarlane LL, Callahan J, Kane EL, Akhurst T, Hicks RJ. Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT. *EJNMMI Research* 2019;9:15.
53. Paul S, Haskali MB, Liow JS, Zoghbi SS, Barth VN, Kolodrubetz MC, Bond MR, Morse CL, Gladding RL, Frankland MP, Kant N, Sliker L, Shcherbinin S, Nuthall HN, Zanotti-Fregonara P, Hanover JA, Jesudason C, Pike VW, Innis RB. Evaluation of a PET Radioligand to Image O-GlcNAcase in Brain and Periphery of Rhesus Monkey and Knock-Out Mouse. *Journal of Nuclear Medicine* 2019;60:129-34.
54. Phillips EJ, Bigliardi P, Bircher AJ, Broyles A, Chang YS, Chung WH, Lehloenya R, Mockenhaupt M, Peter J, Pirmohamed M, Roujeau JC, Shear NH, Tanno LK, Trubiano J, Valluzzi R, Barbaud A. Controversies in drug allergy: Testing for delayed reactions. *Journal of Allergy and Clinical Immunology* 2019;143:66-73.
55. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jager U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak O, Salles G, Maziarz RT. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *New England Journal of Medicine* 2019;380:45-56.
56. Sessler DI, Riedel B. Anesthesia and Cancer Recurrence: Context for Divergent Study Outcomes. *Anesthesiology* 2019;130:3-5.
57. Simmance N, Cortinovis T, Green C, Lunardi K, McPhee M, Steer B, Wai J, Martin T, Porter J. Introducing novel advanced practice roles into the health workforce: Dietitians leading in gastrostomy management. *Nutrition & Dietetics* 2019;76:14-20.
58. Tan FH, Putoczki TL, Stylli SS, Luwor RB. Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies. *Onco Targets Ther.* 2019;12:635-645.
59. Tang PS, Tam CS. BTK/PD-1 blockade for treatment of Richter's transformation. *Lancet Haematology* 2019;6:e59-e60.
60. Teh J, Kearns P, Lawrentschuk N. Primary transitional cell carcinoma of penis - A rare presentation. *Urol Case Rep.* 2019;23:25-26.
61. van der Weyden C, McCormack C, Lade S, Johnstone RW, Prince HM. Rare T-Cell Subtypes. *Cancer Treatment and Research* 2019;176:195-224.
62. Walker AK, Martelli D, Ziegler AI, Lambert GW, Phillips SE, Hill SJ, McAllen RM, Sloan EK. Circulating epinephrine is not required for chronic stress to enhance metastasis. *Psychoneuroendocrinology* 2019;99:191-5.
63. Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, Porter LH, Niranjana B, Whitby ST, Lo J, Huang C, Schittenhelm RB, Anderson KE, Furic L, Wijayarathne PR, Matzaris M, Montgomery MK, Papargiris M, Norden S, Febbraio M, Risbridger GP, Frydenberg M, Nomura DK, Taylor RA. Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. *Science Translational Medicine* 2019;11:eaau5758.
64. Yang Y, Wu L, Shu X, Lu Y, Shu XO, Cai Q, Beeghly-Fadiel A, Li B, Ye F, Berchuck A, Anton-Culver H, Banerjee S, Benitez J, Bjorge L, Brenton JD, Butzow R, Campbell IG, Chang-Claude J, Chen K, Cook LS, Cramer DW, deFazio A, Dennis J, Doherty JA, Dork T, Eccles DM, Edwards DV, Fasching PA, Fortner RT, Gayther SA, Giles GG, Glasspool RM, Goode EL, Goodman MT, Gronwald J, Harris HR, Heitz F, Hildebrandt MA, Hogdall E, Hogdall CK, Huntsman DG, Kar SP, Karlan BY, Kelemen LE, Kiemeny LA, Kjaer SK, Koushik A, Lambrechts D, Le ND, Levine DA, Massuger LF, Matsuo K, May T, McNeish IA, Menon U, Modugno F, Monteiro AN, Moorman PG, Moysich KB, Ness RB, Nevanlinna H, Olsson H, Onland-Moret NC, Park SK, Paul J, Pearce CL, Pejovic T, Phelan CM, Pike MC, Ramus SJ, Riboli E, Rodriguez-Antona C, Romieu I, Sandler DP, Schildkraut JM, Setiawan VW, Shan K, Siddiqui N, Sieh W, Stampfer MJ, Sutphen R, Swerdlow AJ, Szafron LM, Teo SH, Tworoger SS, Tyrer JP, Webb PM, Wentzensen N, White E, Willett WC, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Chenevix-Trench G, Sellers TA, Pharoah PDP, Zheng W, Long J. Genetic Data from Nearly 63,000 Women of European

Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. *Cancer Research* 2019;79:505-17.

65. Yin X, Mason J, Lobachevsky PN, Munforte L, Selbie L, Ball DL, Martin RF, Leong T, Siva S, Martin OA. Radiation Therapy Modulates DNA Repair Efficiency in Peripheral Blood Mononuclear Cells of Patients With Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology, Biology, Physics* 2019;103:521-31.
66. Yuan Y, Arcucci V, Levy SM, Achen MG. Modulation of immunity by lymphatic dysfunction in lymphedema. *Frontiers in Immunology* 2019;10:76.

February 2019

1. Ali AI, Oliver AJ, Samiei T, Chan JD, Kershaw MH, Slaney CY. Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer. *Frontiers in Oncology* 2019;9:56.
2. Bartlett AW, Cann MP, Yeoh DK, Bernard A, Ryan AL, Blyth CC, Kotecha RS, McMullan BJ, Moore AS, Haeusler GM, Clark JE. Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10-year review. *Pediatric Blood & Cancer* 2019;66:e27564.
3. Blagden SP, Hamilton AL, Mileshkin L, Wong S, Michael A, Hall M, Goh JC, Lisyanskaya AS, DeSilvio M, Frangou E, Stronach EA, Gopalakrishna P, Meniawy TM, Gabra H. Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. *Clinical Cancer Research* 2019;25:1472-8.
4. Blaschke SM, Lambert SD, Livingston PM, Aranda S, Boltong A, Schofield P, Chambers SK, Krishnasamy M, Ugalde A. Identifying priorities for cancer caregiver interventions: protocol for a three-round modified Delphi study. *BMJ Open* 2019;9:e024725.
5. Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, Teh CE, Nguyen T, Xu Z, Flensburg C, Lew TE, Majewski IJ, Gray DHD, Westerman DA, Tam CS, Seymour JF, Czabotar PE, Huang DCS, Roberts AW. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. *Cancer Discovery* 2019;9:342-53.
6. Blombery P, Dawson SJ. Circulating tumor DNA for disease monitoring in the era of CAR T-cell therapy. *Leuk Lymphoma*. 2019;60:279-280.
7. Bucknell NW, Ball D. PCI in Small Cell-Review the Cohorts. *Journal of Thoracic Oncology* 2019;14:e59-e60.
8. Clucas D, Fox LC, Wood EM, Hong FS, Gibson J, Bajel A, Szer J, Blombery P, McQuilten ZK, Hiwase D, Firkin F, Cole-Sinclair MF. Revisiting acquired aplastic anaemia: Current concepts in diagnosis and management. *Internal Medicine Journal* 2019;49:152-159.
9. De Ruyscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F. Radiotherapy toxicity. *Nature Reviews Disease Primers* 2019;5:13.
10. Flanagan DJ, Barker N, Di Costanzo NS, Mason EA, Gurney A, Meniel VS, Koushyar S, Austin CR, Ernst M, Pearson HB, Boussioutas A, Clevers H, Pheffe TJ, Vincan E. Frizzled-7 Is Required for Wnt Signaling in Gastric Tumors with and Without Apc Mutations. *Cancer Research* 2019;79:970-81.
11. Hicks DG, Speed TP, Yassin M, Russell SM. Maps of variability in cell lineage trees. *PLoS Computational Biology* 2019;15:e1006745.
12. Hiong A, Thursky KA, Venn G, Teh BW, Haeusler GM, Crane M, Slavin MA, Worth LJ. Impact of a hospital-wide sepsis pathway on improved quality of care and clinical outcomes in surgical patients at a comprehensive cancer centre. *Eur J Cancer Care* 2019;28:e13018.
13. Januszewicz W, Tan WK, Lehovsky K, Debiram-Beecham I, Nuckcheddy T, Moist S, Kadri S, di Pietro M, Boussioutas A, Shaheen NJ, Katzka DA, Dellon ES, Fitzgerald RC. Safety and Acceptability of Esophageal

Cytosponge Cell Collection Device in a Pooled Analysis of Data From Individual Patients. *Clinical Gastroenterology and Hepatology* 2019;17:647-56.

14. Kim TH, Ly C, Christodoulides A, Nowell CJ, Gunning PW, Sloan EK, Rowat AC. Stress hormone signaling through beta-adrenergic receptors regulates macrophage mechanotype and function. *FASEB Journal* 2019;33:3997-4006.
15. Kiss N, Baguley BJ, Ball K, Daly RM, Fraser SF, Granger CL, Ugalde A. Technology-Supported Self-Guided Nutrition and Physical Activity Interventions for Adults With Cancer: Systematic Review. *JMIR Mhealth Uhealth* 2019;7:e12281.
16. Kong G, Grozinsky-Glasberg S, Hofman MS, Akhurst T, Meirovitz A, Maimon O, Krausz Y, Godefroy J, Michael M, Gross DJ, Hicks RJ. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). *European Journal of Nuclear Medicine and Molecular Imaging* 2019;46:718-27.
17. Lau YC, Jongerius K, Wakeman C, Heriot AG, Solomon MJ, Sagar PM, Tekkis PP, Frizelle FA. Influence of the level of sacrectomy on survival in patients with locally advanced and recurrent rectal cancer. *British Journal of Surgery* 2019;106:484-90.
18. Lisy K, Ward A, Schofield P, Hulbert-Williams N, Bishop J, Jefford M. Patient-reported outcomes of sexual and gender minority cancer survivors in Australia. *Psycho-Oncology* 2019;28:442-4.
19. Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. *Journal of Clinical Oncology* 2019;37:559-69.
20. Lok SW, Whittle JR, Vaillant F, Teh CE, Lo LL, Policheni AN, Bergin ART, Desai J, Ftouni S, Gandolfo LC, Liew D, Liu HK, Mann GB, Moodie K, Murugasu A, Pal B, Roberts AW, Rosenthal MA, Shackleton K, Silva MJ, Siow ZR, Smyth GK, Taylor L, Travers A, Yeo B, Yeung MM, Bujak AZ, Dawson SJ, Gray DHD, Visvader JE, Lindeman GJ. A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. *Cancer Discovery* 2019;9:354-69.
21. Lu H, Arshad M, Thornton A, Avesani G, Cunnea P, Curry E, Kanavati F, Liang J, Nixon K, Williams ST, Hassan MA, Bowtell DDL, Gabra H, Fotopoulou C, Rockall A, Aboagye EO. A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. *Nature Communications* 2019;10:764.
22. Matta R, Chapple CR, Fisch M, Heidenreich A, Herschorn S, Kodama RT, Koontz BF, Murphy DG, Nguyen PL, Nam RK. Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review. *European Urology* 2019;75:464-76.
23. Merino D, Weber TS, Serrano A, Vaillant F, Liu K, Pal B, Di Stefano L, Schreuder J, Lin D, Chen Y, Asselin-Labat ML, Schumacher TN, Cameron D, Smyth GK, Papenfuss AT, Lindeman GJ, Visvader JE, Naik SH. Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. *Nature Communications* 2019;10:766.
24. Moran R, Devchand M, Smibert O, Trubiano JA. Antibiotic allergy labels in hospitalized and critically ill adults: A review of current impacts of inaccurate labelling. *British Journal of Clinical Pharmacology* 2019;85:492-500.
25. Qu LG, Lawrentschuk N. Bladder cancer surveillance in patients with spinal cord injuries. *BJU International* 2019;123:379-80.
26. Rademaker M, Rubel DM, Agnew K, Andrews M, Armour KS, Baker C, Foley P, Gebauer K, Goh MS, Gupta M, Marshman G, Prince HM, Sullivan J. Psoriasis and cancer. An Australian/New Zealand narrative. *Australasian Journal of Dermatology* 2019;60:12-8.

27. Salmi TM, Tan VWT, Cox AG. Dissecting metabolism using zebrafish models of disease. *Biochemical Society Transactions* 2019;47:305-15.
28. Sathianathen NJ, Butaney M, Bongiorno C, Konety BR, Bolton DM, Lawrentschuk N. Accuracy of the magnetic resonance imaging pathway in the detection of prostate cancer: a systematic review and meta-analysis. *Prostate Cancer and Prostatic Diseases* 2019;22:39-48.
29. Schmidt B, Eapen RS, Cowan JE, Broering JM, Greene KL, Carroll PR, Cooperberg MR. Practice patterns of primary EBRT with and without ADT in prostate cancer treatment. *Prostate Cancer and Prostatic Diseases* 2019;22:117-24.
30. Turgeon GA, Irvani A, Akhurst T, Beaulieu A, Callahan JW, Bressel M, Cole AJ, Everitt SJ, Siva S, Hicks RJ, Ball DL, Mac Manus MP. What ¹⁸F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria? *Journal of Nuclear Medicine* 2019;60:328-34.
31. Vanhooymissen I, Thomeer MG, Braun LMM, Gest B, van Koeverden S, Willemsen FE, Hunink M, De Man RA, Ijzermans JN, Dwarkasing RS. Inpatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia. *Journal of Magnetic Resonance Imaging* 2019;49:700-10.
32. Wong E, Davis JE, Grigg A, Szer J, Ritchie D. Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation. *Bone Marrow Transplantation* 2019;54:175-189.
33. Zhang AY, Chiam K, Haupt Y, Fox S, Birch S, Tilley W, Butler LM, Knudsen K, Comstock C, Rasiah K, Grogan J, Mahon KL, Bianco-Miotto T, Ricciardelli C, Bohm M, Henshall S, Delprado W, Stricker P, Horvath LG, Kench JG. An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. *International Journal of Cancer* 2019;144:1151-9.

March 2019

1. Banks PD, Lasocki A, Lau PKH, Sandhu S, McArthur G, Shackleton M. Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series. *Health Sci Rep*. 2019;2:e115.
2. Blaschke SM, Gough KC, Chua BH, Francis PA, Cockerell R, Drosdowsky AF, Sheeran L, Krishnasamy M. Implementation of a Multidisciplinary Model of Care for Women With Metastatic Breast Cancer: Challenges and Lessons Learned. *Clinical Breast Cancer* 2019;19:e327-e36.
3. Blombery P, Thompson ER, Prince HM. Molecular Drivers of Breast Implant-Associated Anaplastic Large Cell Lymphoma. *Plast Reconstr Surg*. 2019;143:59S-64S.
4. Britton B, Baker AL, Wolfenden L, Wratten C, Bauer J, Beck AK, McCarter K, Harrowfield J, Isenring E, Tang C, Oldmeadow C, Carter G. In Reply to Lee and Douthit, and Champ and Klement. *International Journal of Radiation Oncology, Biology, Physics* 2019;103:1283-4.
5. Cheng Y, Makara M, Peel E, Fox S, Papenfuss AT, Belov K. Tasmanian devils with contagious cancer exhibit a constricted T-cell repertoire diversity. *Communications Biology* 2019;2:99.
6. Christie EL, Pattnaik S, Beach J, Copeland A, Rashoo N, Fereday S, Hendley J, Alsop K, Brady SL, Lamb G, Pandey A, deFazio A, Thorne H, Bild A, Bowtell DDL. Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. *Nature Communications* 2019;10:1295.
7. Devchand M, Urbancic KF, Khumra S, Douglas AP, Smibert O, Cohen E, Sutherland M, Phillips EJ, Trubiano JA. Pathways to improved antibiotic allergy and antimicrobial stewardship practice: The validation of a beta-lactam antibiotic allergy assessment tool. *The Journal of Allergy and Clinical Immunology In Practice* 2019;7:1063-5.
8. Douglas A, Marshall C, Baines SL, Ritchie D, Szer J, Madigan V, Chan HT, Ballard SA, Howden BP, Buising K, Slavin MA. Utilizing genomic analyses to investigate the first outbreak of vanA vancomycin-resistant

Enterococcus in Australia with emergence of daptomycin non-susceptibility. *Journal of Medical Microbiology* 2019;68:303-308.

9. Forrest LE, Sawyer SD, Hallowell N, James PA, Young MA. High-risk women's risk perception after receiving personalized polygenic breast cancer risk information. *Journal of Community Genetics* 2019;10:197-206.
10. Gray PE, Shadur B, Russell S, Mitchell R, Gallagher K, Thia K, Palasanthiran P, Voskoboinik I. Neonatal Cytomegalovirus Palatal Ulceration and Bocavirus Pneumonitis Associated With a Defect of Lymphocyte Cytotoxicity Caused by Mutations in UNC13D. *Journal of the Pediatric Infectious Diseases Society* 2019;8:73-6.
11. Hamilton DG. Continued Citation of Retracted Radiation Oncology Literature-Do We Have a Problem? *International Journal of Radiation Oncology, Biology, Physics* 2019;103:1036-42.
12. Haupt S, Mejía-Hernández JO, Vijayakumaran R, Keam S, Haupt Y. The long and the short of it: the MDM4 tail so far. *J Mol Cell Biol.* 2019;11:231-244.
13. Jiao Y, Preston S, Garcia-Bustos JF, Baell JB, Ventura S, Le T, McNamara N, Nguyen N, Botteon A, Skinner C, Danne J, Ellis S, Koehler AV, Wang T, Chang BCH, Hofmann A, Jabbar A, Gasser RB. Tetrahydroquinoxalines induce a lethal evisceration phenotype in *Haemonchus contortus* in vitro. *International Journal for Parasitology Drugs and Drug Resistance* 2019;9:59-71.
14. Kelly MJ, So J, Rogers AJ, Gregory G, Li J, Zethoven M, Gearhart MD, Bardwell VJ, Johnstone RW, Vervoort SJ, Kats LM. Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. *Nature Communications* 2019;10:1347.
15. Keogh LA, Steel E, Weideman P, Butow P, Collins IM, Emery JD, Mann GB, Bickerstaffe A, Trainer AH, Hopper LJ, Phillips KA. Consumer and clinician perspectives on personalising breast cancer prevention information. *Breast* 2019;43:39-47.
16. Kipritidis J, Tahir BA, Cazoulat G, Hofman MS, Siva S, Callahan J, Hardcastle N, Yamamoto T, Christensen GE, Reinhardt JM, Kadoya N, Patton TJ, Gerard SE, Duarte I, Archibald-Heeren B, Byrne M, Sims R, Ramsay S, Booth JT, Eslick E, Hegi-Johnson F, Woodruff HC, Ireland RH, Wild JM, Cai J, Bayouth JE, Brock K, Keall PJ. The VAMPIRE challenge: A multi-institutional validation study of CT ventilation imaging. *Medical Physics* 2019;46:1198-217.
17. Kong JC, Guerra GR, Pham T, Mitchell C, Lynch AC, Warriar SK, Ramsay RG, Heriot AG. Prognostic Impact of Tumor-Infiltrating Lymphocytes in Primary and Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. *Diseases of the Colon and Rectum* 2019;62:498-508.
18. Kothari G, Ost P, Cheung P, Blanchard P, Tree AC, van As NJ, Lo SS, Moghanaki D, Loblaw A, Siva S. Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer. *Current Oncology Reports* 2019;21:43.
19. Le BH, Marston C, Kerley C, Eastman P. Facilitating the choice of dying at home or in residential care with the implementation of a palliative care rapid response team in a cancer centre and general hospital. *Palliative Medicine* 2019;33:475-6.
20. Lee KWC, Lord S, Finn RS, Lim E, Martin A, Loi S, Lynch J, Friedlander M, Lee CK. The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. *Breast Cancer Research and Treatment* 2019;174:271-8.
21. Leong TL, Gayevskiy V, Steinfort DP, De Massy MR, Gonzalez-Rajal A, Marini KD, Stone E, Chin V, Havryk A, Plit M, Irving LB, Jennings BR, McCloy RA, Jayasekara WSN, Alamgeer M, Boolell V, Field A, Russell PA, Kumar B, Gough DJ, Szczepny A, Ganju V, Rossello FJ, Cain JE, Papenfuss AT, Asselin-Labat ML, Cowley MJ, Watkins DN. Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer. *Oncogene* 2019;38:1661-75.

22. Li MH, Bolshinsky V, Ismail H, Burbury K, Ho KM, Amin B, Heriot A, Riedel B. A cross-sectional survey of Australian anaesthetists' and surgeons' perceptions of preoperative risk stratification and prehabilitation. *Canadian Journal of Anaesthesia* 2019;66:388-405.
23. Lin KY, Edbrooke L, Granger CL, Denehy L, Frawley HC. The impact of gynaecological cancer treatment on physical activity levels: a systematic review of observational studies. *Brazilian Journal of Physical Therapy* 2019;23:79-92.
24. Lindemann K, Beale PJ, Rossi E, Goh JC, Vaughan MM, Tenney ME, Martyn JK, Sommeijer D, Iglesias JL, Kremmidiotis G, Simpson J, Doolin E, Lavranos TC, Leske A, Veillard AS, Espinoza D, Stockler MR, Rischin D. Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). *Cancer Chemotherapy and Pharmacology* 2019;83:97-105.
25. Lipson-Smith R, White F, White A, Serong L, Cooper G, Price-Bell G, Hyatt A. Co-Design of a Consultation Audio-Recording Mobile App for People With Cancer: The SecondEars App. *JMIR Formative Research* 2019;3:e11111.
26. Lobachevsky PN, Ventura J, Giannakandropoulou L, Forrester H, Palazzolo JS, Haynes NM, Stevenson AW, Hall CJ, Mason J, Pollakis G, Pateras IS, Gorgoulis V, Terzoudi GI, Hamilton JA, Sprung CN, Georgakilas AG, Martin OA. A Functional Immune System Is Required for the Systemic Genotoxic Effects of Localized Irradiation. *International Journal of Radiation Oncology, Biology, Physics* 2019;103:1184-93.
27. Luen SJ, Salgado R, Dieci MV, Vingiani A, Curigliano G, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng E, Andreopoulou E, Castillo M, Adams S, Demaria S, Symmans WF, Michiels S, Loi S. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. *Annals of Oncology* 2019;30:236-42.
28. Marshall KM, Loeliger J, Nolte L, Kelaart A, Kiss NK. Prevalence of malnutrition and impact on clinical outcomes in cancer services: A comparison of two time points. *Clinical Nutrition* 2019;38:644-51.
29. McDowell LJ, Ringash J, Xu W, Chan B, Lu L, Waldron J, Rock K, So N, Huang SH, Giuliani M, Hope A, O'Sullivan B, Bratman SV, Cho J, Kim J, Jang R, Bayley A, Bernstein LJ. A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy. *Radiotherapy and Oncology* 2019;131:179-85.
30. McInnes LE, Noor A, Kysenius K, Cullinane C, Roselt P, McLean CA, Chiu FCK, Powell AK, Crouch PJ, White JM, Donnelly PS. Potential Diagnostic Imaging of Alzheimer's Disease with Copper-64 Complexes That Bind to Amyloid-beta Plaques. *Inorganic Chemistry* 2019;58:3382-95.
31. McKay MJ, Craig J, Kalitsis P, Kozlov S, Verschoor S, Chen P, Lobachevsky P, Vasireddy R, Yan Y, Ryan J, McGillivray G, Savarirayan R, Lavin MF, Ramsay RG, Xu H. A Roberts Syndrome Individual With Differential Genotoxin Sensitivity and a DNA Damage Response Defect. *International Journal of Radiation Oncology, Biology, Physics* 2019;103:1194-202.
32. Mitchell CB, Black B, Sun F, Chrzanowski W, Cooper-White J, Maisonneuve B, Stringer B, Day B, Biro M, O'Neill GM. Tropomyosin Tpm 2.1 loss induces glioblastoma spreading in soft brain-like environments. *Journal of Neuro-Oncology* 2019;141:303-13.
33. Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. *Journal of the National Cancer Institute* 2019;111:210-3.
34. Nzenza TC, Manning T, Ngweso S, Perera M, Sengupta S, Bolton D, Lawrentschuk N. Quality of handwritten surgical operative notes from surgical trainees: a noteworthy issue. *ANZ Journal of Surgery* 2019;89:176-9.

35. Paige EK, Spelman D. Nocardiosis: 7-year experience at an Australian tertiary hospital. *Internal Medicine Journal* 2019;49:373-9.
36. Park SL, Buzzai A, Rautela J, Hor JL, Hochheiser K, Effern M, McBain N, Wagner T, Edwards J, McConville R, Wilmott JS, Scolyer RA, Tuting T, Palendira U, Gyorki D, Mueller SN, Huntington ND, Bedoui S, Holzel M, Mackay LK, Waithman J, Gebhardt T. Tissue-resident memory CD8⁺ T cells promote melanoma-immune equilibrium in skin. *Nature* 2019;565:366-71.
37. Pham T, Carpinteri S, Sampurno S, Pereira L, Roth S, Narasimhan V, Darcy P, Desai J, Heriot AG, Ramsay RG. Novel Vaccine Targeting Colonic Adenoma: a Pre-clinical Model. *Journal of Gastrointestinal Surgery* 2019;23:626-33.
38. Philip J, Collins A, Le B, Sundararajan V, Brand C, Hanson S, Emery J, Hudson P, Mileskin L, Ganiatsas S. A randomised phase II trial to examine feasibility of standardised, early palliative (STEP) care for patients with advanced cancer and their families [ACTRN12617000534381]: a research protocol. *Pilot and Feasibility Studies* 2019;5:44.
39. Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanic M, Reading JL, Joshi K, Henry JY, Ghorani E, Wilson GA, Birkbak NJ, Jamal-Hanjani M, Veeriah S, Szallasi Z, Loi S, Hellmann MD, Feber A, Chain B, Herrero J, Quezada SA, Demeulemeester J, Van Loo P, Beck S, McGranahan N, Swanton C. Neoantigen-directed immune escape in lung cancer evolution. *Nature* 2019;567:479-85.
40. Sahu A, Jefford M, Lai-Kwon J, Thai A, Hicks RJ, Michael M. CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience. *Journal of Oncology* 2019;2019:9032753.
34. Schröder J, Kumar A, Wong SQ. Overview of Fusion Detection Strategies Using Next-Generation Sequencing. *Methods Mol Biol.* 2019;1908:125-138.
41. Siva S, Ball DL. Single Fraction SBRT for Early Stage Lung Cancer-Less is More? *International Journal of Radiation Oncology, Biology, Physics* 2019;103:1085-7.
35. Simbert OC, Guo CW, Khoo C, Thursky KA, Sandhu S, Slavin MA. Microbiome transplantation and modulation of immune related adverse events. *EClinicalMedicine.* 2019;8:10-11.
42. Stephenson MD, Lisy K, Stern CJ, Feyer AM, Fisher L, Aromataris EC. The impact of integrated care for people with chronic conditions on hospital and emergency department utilization: a rapid review. *International Journal of Evidence-Based Healthcare* 2019;17:14-26.
43. Sun Y, Reynolds HM, Parameswaran B, Wraith D, Finnegan ME, Williams S, Haworth A. Multiparametric MRI and radiomics in prostate cancer: a review. *Australasian Physical and Engineering Sciences in Medicine* 2019;42:3-25.
44. Sutherland S, Meiser B, Kaur R, Mitchell G, Kirk J, Peate M, Tim Wong WK, Goodwin A. Assessing the medical workforces perceived barriers to the prescription of risk-reducing medication for women at high-risk of breast cancer. *Breast Journal* 2019;25:34-40.
36. Svensson MN, Doody KM, Schmiedel BJ, Bhattacharyya S, Panwar B, Wiede F, Yang S, Santelli E, Wu DJ, Sacchetti C, Gujar R, Seumois G, Kiosses WB, Aubry I, Kim G, Mydel P, Sakaguchi S, Kronenberg M, Tiganis T, Tremblay ML, Ay F, Vijayanand P, Bottini N. Reduced expression of phosphatase PTPN2 promotes pathogenic conversion of Tregs in autoimmunity. *J Clin Invest.* 2019;129:1193-1210.
45. Terry MB, Daly MB, Phillips KA, Ma X, Zeinomar N, Leoce N, Dite GS, MacInnis RJ, Chung WK, Knight JA, Southey MC, Milne RL, Goldgar D, Giles GG, Weideman PC, Glendon G, Buchsbaum R, Andrulis IL, John EM, Buys SS, Hopper JL. Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk. *Journal of the National Cancer Institute* 2019;111:331-4.
46. Trigos AS, Pearson RB, Papenfuss AT, Goode DL. Somatic mutations in early metazoan genes disrupt regulatory links between unicellular and multicellular genes in cancer. *eLife* 2019;8:e40947.
47. Valentine JC, Haeusler G, Worth L, Thursky K. Sepsis incidence and mortality are underestimated in Australian intensive care unit administrative data. *Medical Journal of Australia* 2019;210:188-188.e1.

48. Valentine JC, Morrissey CO, Tacey MA, Liew D, Patil S, Peleg AY, Ananda-Rajah MR. A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005 - 2016. *BMC Infectious Diseases* 2019;19:274.
49. Van Der Weyden C, Dickinson M, Whisstock J, Prince HM. Brentuximab vedotin in T-cell lymphoma. *Expert Review of Hematology* 2019;12:5-19.
50. Vapiwala N, Hofman MS, Murphy DG, Williams S, Sweeney C. Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. *Journal of Clinical Oncology* 2019;37:765-9.
37. Wall M, Blombery P. What does good FISHing look like in MDS? *Leuk Lymphoma*. 2019;60:571-572.
51. Wirth A, Prince HM, Roos D, Gibson J, O'Brien P, Zannino D, Khodr B, Stone JM, Davis S, Hertzberg M. A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03). *International Journal of Radiation Oncology, Biology, Physics* 2019;103:1158-66.
52. Yap A, Lopez-Olivo MA, Dubowitz J, Hiller J, Riedel B. Anesthetic technique and cancer outcomes: a meta-analysis of total intravenous versus volatile anesthesia. *Canadian Journal of Anaesthesia* 2019;66:546-61.

April 2019

1. Ahler E, Register AC, Chakraborty S, Fang L, Dieter EM, Sitko KA, Vidadala RSR, Trevillian BM, Golkowski M, Gelman H, Stephany JJ, Rubin AF, Merritt EA, Fowler DM, Maly DJ. A Combined Approach Reveals a Regulatory Mechanism Coupling Src's Kinase Activity, Localization, and Phosphotransferase-Independent Functions. *Molecular Cell* 2019;74:393-408.
2. Alexander W, Miller G, Alexander P, Henderson MA, Webb A. 'Scalp coordinate system': a new tool to accurately describe cutaneous lesions on the scalp: a pilot study. *ANZ Journal of Surgery* 2019;89:E127-31.
3. Allaway Z, Phillips RS, Thursky KA, Haeusler GM. Nonneutropenic fever in children with cancer: A scoping review of management and outcome. *Pediatric Blood & Cancer* 2019;66:e27634.
4. Ball D, Herschtal A. SABR versus conventional fractionation regimens in NSCLC - Authors' reply. *Lancet Oncology* 2019;20:e232.
5. Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, Chesson B, Herschtal A, Vanevski M, Rezo A, Elder C, Skala M, Wirth A, Wheeler G, Lim A, Shaw M, Schofield P, Irving L, Solomon B. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. *Lancet Oncology* 2019;20:494-503.
6. Chaturantabut S, Shwartz A, Evason KJ, Cox AG, Labella K, Schepers AG, Yang S, Acuna M, Houvras Y, Mancio-Silva L, Romano S, Gorelick DA, Cohen DE, Zon LI, Bhatia SN, North TE, Goessling W. Estrogen Activation of G-Protein-Coupled Estrogen Receptor 1 Regulates Phosphoinositide 3-Kinase and mTOR Signaling to Promote Liver Growth in Zebrafish and Proliferation of Human Hepatocytes. *Gastroenterology* 2019;156:1788-804.
7. Chi L, Burrows AD, Anderson RL. Bone morphogenetic protein signalling in breast cancer progression. *Growth Factors* 2019;37:12-28.
8. Crozier J, Papa N, Perera M, Ngo B, Bolton D, Sengupta S, Lawrentschuk N. Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis. *World Journal of Urology* 2019;37:667-90.
9. Dawson SJ. Characterizing the Cancer Genome in Blood. *Cold Spring Harbor Perspectives in Medicine* 2019;9:a026880.

10. Delbridge ARD, Kueh AJ, Ke F, Zamudio NM, El-Saafin F, Jansz N, Wang GY, Iminoff M, Beck T, Haupt S, Hu Y, May RE, Whitehead L, Tai L, Chiang W, Herold MJ, Haupt Y, Smyth GK, Thomas T, Blewitt ME, Strasser A, Voss AK. Loss of p53 Causes Stochastic Aberrant X-Chromosome Inactivation and Female-Specific Neural Tube Defects. *Cell Reports* 2019;27:442-54.
11. Dieras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS. Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. *Journal of the National Cancer Institute* 2019;111:419-30.
12. Duchesne GM. Effective and well tolerated: where do these drugs fit now? *Lancet Oncology* 2019;20:469-470.
13. Farnsworth RH, Karnezis T, Maciburko SJ, Mueller SN, Stacker SA. The interplay between lymphatic vessels and chemokines. *Front Immunol.* 2019;10:518.
14. Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomaki K, Andrulis IL, Anton-Culver H, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Azzollini J, Balmana J, Barnes DR, Barrowdale D, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bialkowska K, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Borg A, Brauch H, Brenner H, Broeks A, Burwinkel B, Caldes T, Caligo MA, Campa D, Campbell I, Canzian F, Carter J, Carter BD, Castela JE, Chang-Claude J, Chanock SJ, Christiansen H, Chung WK, Claes KBM, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, de la Hoya M, Dennis J, Devilee P, Diez O, Dork T, Dunning AM, Dwek M, Eccles DM, Ejlertsen B, Ellberg C, Engel C, Eriksson M, Fasching PA, Fletcher O, Flyger H, Friedman E, Frost D, Gabrielson M, Gago-Dominguez M, Ganz PA, Gapstur SM, Garber J, Garcia-Closas M, Garcia-Saenz JA, Gaudet MM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, Gonzalez-Neira A, Greene MH, Gronwald J, Guenel P, Haiman CA, Hall P, Hamann U, He W, Heyworth J, Hogervorst FBL, Hollestelle A, Hoover RN, Hopper JL, Hulick PJ, Humphreys K, Imyanitov EN, Isaacs C, Jakimovska M, Jakubowska A, James PA, Janavicius R, Jankowitz RC, John EM, Johnson N, Joseph V, Karlan BY, Khusnutdinova E, Kiiski JI, Ko YD, Jones ME, Konstantopoulou I, Kristensen VN, Laitman Y, Lambrechts D, Lazaro C, Leslie G, Lester J, Lesueur F, Lindstrom S, Long J, Loud JT, Lubinski J, Makalic E, Mannermaa A, Manoochehri M, Margolin S, Maurer T, Mavroudis D, McGuffog L, Meindl A, Menon U, Michailidou K, Miller A, Montagna M, Moreno F, Moserle L, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Nevelsteen I, Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olah E, Olopade OI, Olsson H, Osorio A, Papp J, Park-Simon TW, Parsons MT, Pedersen IS, Peixoto A, Peterlongo P, Pharoah PDP, Plaseska-Karanfilska D, Poppe B, Presneau N, Radice P, Rantala J, Rennert G, Risch HA, Saloustros E, Sanden K, Sawyer EJ, Schmidt MK, Schmutzler RK, Sharma P, Shu XO, Simard J, Singer CF, Soucy P, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Swerdlow AJ, Tapper WJ, Taylor JA, Teixeira MR, Terry MB, Teule A, Thomassen M, Thone K, Thull DL, Tischkowitz M, Toland AE, Torres D, Truong T, Tung N, Vachon CM, van Asperen CJ, van den Ouweland AMW, van Rensburg EJ, Vega A, Viel A, Wang Q, Wappenschmidt B, Weitzel JN, Wendt C, Winqvist R, Yang XR, Yannoukakos D, Ziogas A, Kraft P, Antoniou AC, Zheng W, Easton DF, Milne RL, Beesley J, Chenevix-Trench G. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications* 2019;10:1741.
15. Freudenberg LS, Hicks RJ, Beyer T. An International Survey on Clinical Reporting of PET/CT Examinations: A Starting Point for Cross-Specialty Engagement. *Journal of Nuclear Medicine* 2019;60:480-5.
16. Frolidi F, Pachnis P, Szuperak M, Costas O, Fernando T, Gould AP, Cheng LY. Histidine is selectively required for the growth of Myc-dependent dedifferentiation tumours in the Drosophila CNS. *EMBO Journal* 2019;38:e99895.
17. Frowen J. Dysphagia in patients with non-head and neck cancer. *Current Opinion in Otolaryngology & Head and Neck Surgery* 2019;27:162-7.
18. Gray ES, Witkowski T, Pereira M, Calapre L, Herron K, Irwin D, Chapman B, Khattak MA, Raleigh J, Hatzimihalis A, Cebon J, Sandhu S, McArthur GA, Millward M, Ziman M, Dobrovic A, Wong SQ.

Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. *Journal of Molecular Diagnostics* 2019;21:418-26.

19. Hapgood G, Stone JM, Zannino D, George A, Marlton P, Prince HM, Hui CH, Prosser I, Lewis ID, Bradstock K, Seymour JF. A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. *Leukemia and Lymphoma* 2019;60:904-11.
20. Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A. Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. *European Journal of Cancer* 2019;112:29-31.
21. Hong A, Shanahan M, Schenberg T, Inder W, MacIsaac R, James P, Sachithanandan N. Higher risk of pheochromocytoma/paraganglioma (Phaeo-Pgl) in SDHD than SDHB carriers: an Australian cohort study. *Internal Medicine Journal* 2019;49:529-32.
22. Honigman AD, Lai F, Elakis J, Prall O, Goh M, McCormack C. Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous pemphigoid in a single patient. *Clinical Case Reports* 2019;7:773-5.
23. Jeong W, Keighley C, Wolfe R, Lee WL, Slavin MA, Chen SC, Kong DCM. Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports. *International Journal of Antimicrobial Agents* 2019;53:589-97.
24. Karnezis T, Farnsworth RH, Harris NC, Williams SP, Caesar C, Byrne DJ, Herle P, Macheda ML, Shayan R, Zhang YF, Yazar S, Takouridis SJ, Gerard C, Fox SB, Achen MG, Stacker SA. CCL27/CCL28-CCR10 Chemokine Signaling Mediates Migration of Lymphatic Endothelial Cells. *Cancer Research* 2019;79:1558-72.
25. Kaur R, Meiser B, Yanes T, Young MA, Barlow-Stewart K, Roscioli T, Smith S, James PA. Development and pilot testing of a leaflet informing women with breast cancer about genomic testing for polygenic risk. *Familial Cancer* 2019;18:147-52.
26. Keall P, Kron T, Zaidi H. In the future, emission-guided radiation therapy will play a critical role in clinical radiation oncology. *Medical Physics* 2019;46:1519-22.
27. Kehm RD, Hopper JL, John EM, Phillips KA, MacInnis RJ, Dite GS, Milne RL, Liao Y, Zeinomar N, Knight JA, Southey MC, Vahdat L, Kornhauser N, Cigler T, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S, Andrulis IL, Buys SS, Daly MB, Terry MB. Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. *Breast Cancer Research* 2019;21:52.
28. Kenealy M, Hertzberg M, Benson W, Taylor K, Cunningham I, Stevenson W, Hiwase D, Eek R, Zantomio D, Jong S, Wall M, Blombery P, Gerber T, Debrincat M, Zannino D, Seymour JF. Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. *Haematologica* 2019;104:700-9.
29. Kroon HM, Coventry BJ, Henderson MA, Barbour A, Serpell J, Smithers BM, Thompson JF. Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study. *European Journal of Surgical Oncology* 2019;45:832-7.
30. Lawrenson K, Song F, Hazelett DJ, Kar SP, Tyrer J, Phelan CM, Corona RI, Rodriguez-Malave NI, Seo JH, Adler E, Coetzee SG, Segato F, Fonseca MAS, Amos CI, Carney ME, Chenevix-Trench G, Choi J, Doherty JA, Jia W, Jin GJ, Kim BG, Le ND, Lee J, Li L, Lim BK, Adenan NA, Mizuno M, Park B, Pearce CL, Shan K, Shi Y, Shu XO, Sieh W, Thompson PJ, Wilkens LR, Wei Q, Woo YL, Yan L, Karlan BY, Freedman ML, Noushmehr H, Goode EL, Berchuck A, Sellers TA, Teo SH, Zheng W, Matsuo K, Park S, Chen K, Pharoah PDP, Gayther SA, Goodman MT. Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. *Gynecologic Oncology* 2019;153:343-55.

31. Lee B, Gibbs P. Inflammation, Biomarkers and Immuno-Oncology Pathways in Pancreatic Cancer. *Journal of Personalized Medicine* 2019;9:20.
32. Lee RS, Zhang L, Berger A, Lawrence MG, Song J, Niranjana B, Davies RG, Lister NL, Sandhu SK, Rubin MA, Risbridger GP, Taylor RA, Rickman DS, Horvath LG, Daly RJ. Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. *Neoplasia* 2019;21:389-400.
33. Liu H, Peng L, So J, Tsang KH, Chong CH, Mak PHS, Chan KM, Chan SY. TSPYL2 Regulates the Expression of EZH2 Target Genes in Neurons. *Mol Neurobiol.* 2019;56:2640-2652.
34. Magnusson M, Beath K, Cooter R, Locke M, Prince HM, Elder E, Deva AK. The Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand Confirms the Highest Risk for Grade 4 Surface Breast Implants. *Plastic and Reconstructive Surgery* 2019;143:1285-92.
35. Markham JF, Yerneni S, Ryland GL, Leong HS, Fellowes A, Thompson ER, De Silva W, Kumar A, Lupat R, Li J, Ellul J, Fox S, Dickinson M, Papenfuss AT, Blombery P. CNspector: a web-based tool for visualisation and clinical diagnosis of copy number variation from next generation sequencing. *Scientific Reports* 2019;9:6426.
36. Martyn M, Kanga-Parabiah A, Lynch E, James PA, Macciocchia I, Trainer AH, Halliday J, Keogh L, Wale J, Winship I, Bogwitz M, Valente G, Walsh M, Downie L, Amor D, Wallis M, Cunningham F, Burgess M, Brown NJ, Jarmolowicz A, Lunke S, Goranitis I, Gaff CL. A novel approach to offering additional genomic findings-A protocol to test a two-step approach in the healthcare system. *Journal of Genetic Counseling* 2019;28:388-97.
37. McCabe MJ, Pinese M, Chan CL, Sheriff N, Thompson TJ, Grady J, Wong M, Gauthier MA, Puttick C, Gayevskiy V, Hajdu E, Wong SQ, Barrett W, Earls P, Lukeis R, Cheng YY, Lin RCY, Thomas DM, Watkins DN, Dinger ME, McCormack AI, Cowley MJ. Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases. *Cold Spring Harbor Molecular Case Studies* 2019;5:a003764.
38. Minson AG, Cummins K, Fox L, Costello B, Yeung D, Cleary R, Forsyth C, Tatarczuch M, Burbury K, Motorna O, Shortt J, Fleming S, McQuillan A, Schwarzer A, Harrup R, Holmes A, Ratnasingam S, Chan KL, Hsu WH, Ashraf A, Putt F, Grigg A. The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia. *Blood Advances* 2019;3:1084-91.
39. Mitchell CB, Phillips WA. Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations. *Biomolecules* 2019;9:158.
40. Narasimhan V, Wein D, Rajkumar A, Farmer C, Warriar S. Rare finding of a giant ischioanal lipoma. *ANZ Journal of Surgery* 2019;89:604-6.
41. Paterson BM, Cullinane C, Crouch PJ, White AR, Barnham KJ, Roselt PD, Noonan W, Binns D, Hicks RJ, Donnelly PS. Modification of Biodistribution and Brain Uptake of Copper Bis(thiosemicarbazonato) Complexes by the Incorporation of Amine and Polyamine Functional Groups. *Inorganic Chemistry* 2019;58:4540-52.
42. Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, Oosterwijk JC, Chung WK, Evans DG, Engel C, Kast K, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Aittomaki K, Alducci E, Andrulis IL, Arun BK, Ausems M, Azzollini J, Barouk-Simonet E, Barwell J, Belotti M, Benitez J, Berger A, Borg A, Bradbury AR, Brunet J, Buys SS, Caldes T, Caligo MA, Campbell I, Caputo SM, Chiquette J, Claes KBM, Margriet Collee J, Couch FJ, Coupier I, Daly MB, Davidson R, Diez O, Domchek SM, Donaldson A, Dorfling CM, Eeles R, Feliubadalo L, Foretova L, Fowler J, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Glendon G, Godwin AK, Gomez Garcia EB, Gronwald J, Hahnen E, Hamann U, Henderson A, Hendricks CB, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, Kaczmarek K, Kang E, Karlan BY, Kets CM, Kim SW, Kim Z, Kwong A, Laitman Y, Lasset C, Hyuk Lee M, Won Lee J, Lee J, Lester J, Lesueur F, Loud JT, Lubinski J, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A,

Montagna M, Mooij TM, Morrison PJ, Mouret-Fourme E, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Nielsen FC, Nussbaum RL, Offit K, Olah E, Ong KR, Ottini L, Park SK, Peterlongo P, Pfeiler G, Phelan CM, Poppe B, Pradhan N, Radice P, Ramus SJ, Rantala J, Robson M, Rodriguez GC, Schmutzler RK, Hutten Selkirk CG, Shah PD, Simard J, Singer CF, Sokolowska J, Stoppa-Lyonnet D, Sutter C, Yen Tan Y, Teixeira RM, Teo SH, Terry MB, Thomassen M, Tischkowitz M, Toland AE, Tucker KM, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Yannoukakos D, Greene MH, Rookus MA, Easton DF, Chenevix-Trench G, Antoniou AC, Goldgar DE, Olopade OI, Rebbeck TR, Huo D. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute* 2019;111:350-64.

43. Regan MM, Fleming GF, Walley B, Francis PA, Pagani O. Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows. *Journal of Clinical Oncology* 2019;37:862-6.
44. Rios AC, Capaldo BD, Vaillant F, Pal B, van Ineveld R, Dawson CA, Chen Y, Nolan E, Fu NY, Jackling FC, Devi S, Clouston D, Whitehead L, Smyth GK, Mueller SN, Lindeman GJ, Visvader JE. Intracolonial Plasticity in Mammary Tumors Revealed through Large-Scale Single-Cell Resolution 3D Imaging. *Cancer Cell* 2019;35:618-32.
45. Roviello G, Corona SP, Aieta M, Roudi R. Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy. *Cancer Biotherapy & Radiopharmaceuticals* 2019;34:141-6.
46. Rowley SM, Mascarenhas L, Devereux L, Li N, Amarasinghe KC, Zethoven M, Lee JEA, Lewis A, Morgan JA, Limb S, Young MA, James PA, Trainer AH, Campbell IG. Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility. *Genetic Medicine* 2019;21:913-22.
47. Russell L, Pascoe MC, Seymour JF, Aranda S, Butow P, Gough K, Schofield P. The trials and tribulations of conducting an m-health pilot randomized controlled trial to improve oral cancer therapy adherence: recommendations for future multisite, non-drug clinical trials. *BMC Research Notes* 2019;12:226.
48. Sathianathen NJ, Kwaan M, Lawrentschuk N, Weight CJ, Kim SP, Murphy DG, Moon DA, Konety BR. Adverse impact of malnutrition markers on major abdominopelvic cancer surgery. *ANZ Journal of Surgery* 2019;89:509-14.
49. Semira C, Wong HL, Field K, Lee M, Lee B, Nott L, Shapiro J, Wong R, Tie J, Tran B, Richardson G, Zimet A, Lipton L, Tamjid B, Burge M, Ma B, Johns J, Harold M, Gibbs P. Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence? *Internal Medicine Journal* 2019;49:446-54.
50. Slavin MA, Worth LJ, Seymour JF, Thursky KA. Better Sepsis Management Rather Than Fluoroquinolone Prophylaxis for Patients With Cancer-Related Immunosuppression. *Journal of Clinical Oncology* 2019;37:1139-40.
51. Tan FH, Bai Y, Saintigny P, Darido C. mTOR Signalling in Head and Neck Cancer: Heads Up. *Cells* 2019;8:333.
52. Terry MB, Liao Y, Whittmore AS, Leoce N, Buchsbaum R, Zeinomar N, Dite GS, Chung WK, Knight JA, Southey MC, Milne RL, Goldgar D, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S, Andrulis IL, John EM, Phillips KA, Daly MB, Buys SS, Hopper JL, MacInnis RJ. 10-year performance of four models of breast cancer risk: a validation study. *Lancet Oncology* 2019;20:504-17.
53. Toss MS, Miligy IM, Gorringer KL, McCaffrey L, Alkawaz A, Abidi A, Ellis IO, Green AR, Rakha EA. Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. *Modern Pathology* 2019;32:639-49.
54. Trubiano JA, Douglas AP, Goh M, Slavin MA, Phillips EJ. The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts. *Journal of Allergy and Clinical Immunology in Practice* 2019;7:1341-3.

55. Tseng YD, Ng AK, Wirth A. New tools of the trade: parsing out the role of radiotherapy for early-stage diffuse large B-cell lymphoma. *Leukemia and Lymphoma* 2019;60:861-3.
56. Ugalde A, Gaskin CJ, Rankin NM, Schofield P, Boltong A, Aranda S, Chambers S, Krishnasamy M, Livingston PM. A systematic review of cancer caregiver interventions: Appraising the potential for implementation of evidence into practice. *Psycho-Oncology* 2019;28:687-701.
57. Veera J, Lim K, Dowling JA, O'Connor C, Holloway LC, Vinod SK. Dedicated MRI simulation for cervical cancer radiation treatment planning: Assessing the impact on clinical target volume delineation. *Journal of Medical Imaging and Radiation Oncology* 2019;63:236-43.
58. Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Kumar AR, Thang SP, Eu P, Scalzo M, Murphy D, Williams S, Hicks RJ, Hofman MS. Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. *Journal of Nuclear Medicine* 2019;60:517-23.
59. Wilson AS, Law HD, Knobbe-Thomsen CB, Kearney CJ, Oliaro J, Binsfeld C, Burgio G, Starrs L, Brenner D, Randall KL, Brustle A. Protection from EAE in DOCK8 mutant mice occurs despite increased Th17 cell frequencies in the periphery. *European Journal of Immunology* 2019;49:770-81.
60. Yang Y, Swierczak A, Ibahim M, Paiva P, Cann L, Stevenson AW, Crosbie JC, Anderson RL, Rogers PAW. Synchrotron microbeam radiotherapy evokes a different early tumor immunomodulatory response to conventional radiotherapy in EMT6.5 mammary tumors. *Radiotherapy and Oncology* 2019;133:93-99.
61. Yusof HH, Lee HC, Seth EA, Wu X, Hewitt CA, Scott HS, Cheah PS, Li YM, Chau DM, Ling KH. Expression Profiling of Notch Signalling Pathway and Gamma-Secretase Activity in the Brain of Ts1Cje Mouse Model of Down Syndrome. *Journal of Molecular Neuroscience* 2019;67:632-42.
62. Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, Tilly H, Cartron G, Chamuleau MED, Goy A, Tam CS, Lugtenburg PJ, Petrich AM, Sinha A, Samineni D, Herter S, Ingalla E, Szafer-Glusman E, Klein C, Sampath D, Kornacker M, Mobasher M, Morschhauser F. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. *Blood* 2019;133:1964-76.

May 2019

1. Alexander M, Sryjanen R, Ball D, MacManus M, Burbury K. The potential "additive" thromboembolic risk of radiotherapy. *Asia-Pacific Journal of Clinical Oncology* 2019;15:183-4.
2. Alfano CM, Jefford M, Maher J, Birken SA, Mayer DK. Building Personalized Cancer Follow-up Care Pathways in the United States: Lessons Learned From Implementation in England, Northern Ireland, and Australia. *American Society of Clinical Oncology Education Book* 2019;39:625-39.
3. Bast RC, Jr., Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Jr., Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. *Cancer* 2019;125:1963-72.
4. Beatty L, Kemp E, Coll JR, Turner J, Butow P, Milne D, Yates P, Lambert S, Wootten A, Yip D, Koczwara B. Finding My Way: results of a multicentre RCT evaluating a web-based self-guided psychosocial intervention for newly diagnosed cancer survivors. *Supportive Care in Cancer* 2019;27:2533-44.
5. Blaschke SM, Schofield P, Taylor K, Ugalde A. Common dedication to facilitating good dying experiences: Qualitative study of end-of-life care professionals' attitudes towards voluntary assisted dying. *Palliative Medicine* 2019;33:562-9.
6. Brandao RD, Mensaert K, Lopez-Perolio I, Tserpelis D, Xenakis M, Lattimore V, Walker LC, Kvist A, Vega A, Gutierrez-Enriquez S, Diez O, de la Hoya M, Spurdle AB, De Meyer T, Blok MJ. Targeted RNA-seq

successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes. *International Journal of Cancer* 2019;145:401-14.

7. Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. *Blood* 2019;133:2031-42.
8. Cheasley D, Li N, Rowley SM, Elder K, Mann GB, Loi S, Savas P, Goode DL, Kader T, Zethoven M, Semple T, Fox SB, Pang JM, Byrne D, Devereux L, Nickson C, Procopio P, Lee G, Hughes S, Saunders H, Fujihara KM, Kuykhoven K, Connaughton J, James PA, Gorringer KL, Campbell IG. Molecular comparison of interval and screen-detected breast cancers. *The Journal of Pathology* 2019;248:243-52.
9. Chew SM, Sweeney N, Kidd SE, Reed C. *Candida auris* arriving on our shores: an Australian microbiology laboratory's experience. *Pathology* 2019;51:431-3.
10. Correa RJM, Louie AV, Staehler M, Warner A, Gandhidasan S, Ponsky L, Ellis R, Kaplan I, Mahadevan A, Chu W, Swaminath A, Onishi H, Teh BS, Lo SS, Muacevic A, Siva S. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK. *The Journal of Urology* 2019;201:1097-104.
11. Dent LG, Manning SA, Kroeger B, Williams AM, Saiful Hilmi AJ, Crea L, Kondo S, Horne-Badovinac S, Harvey KF. The dPix-Git complex is essential to coordinate epithelial morphogenesis and regulate myosin during *Drosophila* egg chamber development. *PLoS Genet.* 2019;15:e1008083.
12. Devchand M, Kirkpatrick CMJ, Stevenson W, Garrett K, Perera D, Khumra S, Urbancic K, Grayson ML, Trubiano JA. Evaluation of a pharmacist-led penicillin allergy de-labelling ward round: a novel antimicrobial stewardship intervention. *The Journal of Antimicrobial Chemotherapy* 2019;74:1725-30.
13. Duncan C, Omran GJ, Teh J, Davis NF, Bolton DM, Lawrentschuk N. Erectile dysfunction: a global review of intracavernosal injectables. *World Journal of Urology* 2019;37:1007-14.
14. Farshid G, Bilous M, Morey A, Fox S, Lakhani S, Loi S, Bell R, Spillane A. ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. *Pathology* 2019;51:345-8.
15. Ferreira G, Iravani A, Hofman MS, Hicks RJ. Intra-individual comparison of ⁶⁸Ga-PSMA-11 and ¹⁸F-DCFPyL normal-organ biodistribution. *Cancer Imaging* 2019;19:23.
16. Froughi S, Wong HL, Gately L, Lee M, Simons K, Tie J, Burgess AW, Gibbs P. Registry-based randomized clinical trials as a method to improve cancer care in Australia. *Asia-Pacific Journal of Clinical Oncology* 2019;15:188-9.
17. Fortuno C, Cipponi A, Ballinger ML, Tavtigian SV, Olivier M, Ruparel V, Haupt Y, Haupt S, Study ISK, Tucker K, Spurdle AB, Thomas DM, James PA. A quantitative model to predict pathogenicity of missense variants in the TP53 gene. *Human Mutation* 2019;40:788-800.
18. Goldie SJ, Chincarini G, Darido C. Targeted Therapy Against the Cell of Origin in Cutaneous Squamous Cell Carcinoma. *International Journal of Molecular Sciences* 2019;20:E2201.
19. Hung TJ, McLean L, Mitchell C, Pascoe C, Lawrentschuk N, Murphy DG, Iravani A, Singh D, Hofman MS, Zidan L, Akhurst T, Lewin J, Hicks RJ. The role of ¹⁸F-FDG-PET/CT in evaluating retroperitoneal masses - Keeping your eye on the ball! *Cancer Imaging* 2019;19:28.
20. Jones JRA, Berney S, Connolly B, Waterland JL, Denehy L, Griffith DM, Puthuchery ZA. Socioeconomic Position and Health Outcomes Following Critical Illness: A Systematic Review. *Critical Care Medicine* 2019;47:e512-21.
21. Keighley C, Chen SC, Marriott D, Pope A, Chapman B, Kennedy K, Bak N, Underwood N, Wilson HL, McDonald K, Darvall J, Halliday C, Kidd S, Nguyen Q, Hajkovicz K, Sorrell TC, Van Hal S, Slavin MA. *Candidaemia* and a risk predictive model for overall mortality: a prospective multicentre study. *BMC Infectious Diseases* 2019;19:445.

22. Kerage D, Sloan EK, Mattarollo SR, McCombe PA. Interaction of neurotransmitters and neurochemicals with lymphocytes. *Journal of Neuroimmunology* 2019;332:99-111.
23. Kiss N, Beraldo J, Everitt S. Early Skeletal Muscle Loss in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation and Relationship to Survival. *Supportive Care in Cancer* 2019;27:2657-64.
24. Lawrentschuk N. Editorial Comment. *The Journal of Urology* 2019;201:1104.
25. Mardiana S, Lai J, House IG, Beavis PA, Darcy PK. Switching on the green light for chimeric antigen receptor T-cell therapy. *Clinical & Translational Immunology* 2019;8:e1046.
26. McEvoy CR, Xu H, Smith K, Etemadmoghadam D, Leong HS, Choong DY, Byrne DJ, Iravani A, Beck S, Mileskin L, Tothill RW, Bowtell DD, Bates BM, Nastevski V, Browning J, Bell AH, Khoo C, Desai J, Fellowes AP, Fox SB, Prall OW. Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. *Journal of Clinical Investigation* 2019;129:1940-5.
27. Miligy IM, Toss MS, Gorringer KL, Lee AHS, Ellis IO, Green AR, Rakha EA. The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. *British Journal of Cancer* 2019;120:1075-82.
28. Murphy DG, Azad AA, Sandhu S, Violet J, Hofman MS. Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics. *European Urology* 2019;75:927-8.
29. Parente P, Chan BA, Hughes BGM, Jasas K, Joshi R, Kao S, Hegi-Johnson F, Hui R, McLaughlin-Barrett S, Nordman I, Stone E. Patterns of care for stage III non-small cell lung cancer in Australia. *Asia-Pacific Journal of Clinical Oncology* 2019;15:93-100.
30. Rademaker M, Agnew K, Anagnostou N, Andrews M, Armour K, Baker C, Foley P, Gebauer K, Gupta M, Marshman G, Rubel D, Sullivan J, Wong LC. Psoriasis and infection. A clinical practice narrative. *Australasian Journal of Dermatology* 2019;60:91-98.
31. Reynolds HM, Williams S, Jackson P, Mitchell C, Hofman MS, Hicks RJ, Murphy DG, Haworth A. Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework. *BJU International* 2019;123:1020-30.
32. Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. *Journal of Clinical Oncology* 2019;37:1159-68.
33. Russell L, Ugalde A, Orellana L, Milne D, Krishnasamy M, Chambers R, Austin DW, Livingston PM. A pilot randomised controlled trial of an online mindfulness-based program for people diagnosed with melanoma. *Supportive Care in Cancer* 2019;27:2735-46.
34. Saner FAM, Herschtal A, Nelson BH, deFazio A, Goode EL, Ramus SJ, Pandey A, Beach JA, Fereday S, Berchuck A, Lheureux S, Pearce CL, Pharoah PD, Pike MC, Garsed DW, Bowtell DDL. Going to extremes: determinants of extraordinary response and survival in patients with cancer. *Nature Reviews Cancer* 2019;19:339-48.
35. Sathianathen NJ, Konety BR, Alarid-Escudero F, Lawrentschuk N, Bolton DM, Kuntz KM. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. *European Urology* 2019;75:910-7.
36. Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology* 2019;37:1370-9.

37. Smith P, Godde N, Rubio S, Tekeste M, Vladar EK, Axelrod JD, Henderson DJ, Milgrom-Hoffman M, Humbert PO, Hinck L. VANG2 regulates luminal epithelial organization and cell turnover in the mammary gland. *Scientific Reports* 2019;9:7079.
38. Somers K, Wen VW, Middlemiss SMC, Osborne B, Forgham H, Jung M, Karsa M, Clifton M, Bongers A, Gao J, Mayoh C, Raoufi-Rad N, Kusnadi EP, Hannan KM, Scott DA, Kwek A, Liu B, Flemming C, Chudakova DA, Pandher R, Failes TW, Lim J, Angeli A, Osterman AL, Imamura T, Kees UR, Supuran CT, Pearson RB, Hannan RD, Davis TP, McCarroll J, Kavallaris M, Turner N, Gudkov AV, Haber M, Norris MD, Henderson MJ. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. *Oncogene*. 2019;38:3824-3842.
39. Steiner E, Shieh CC, Caillet V, Booth J, O'Brien R, Briggs A, Hardcastle N, Jayamanne D, Szymura K, Eade T, Keall P. Both four-dimensional computed tomography and four-dimensional cone beam computed tomography under-predict lung target motion during radiotherapy. *Radiotherapy and Oncology* 2019;135:65-73.
40. Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, Gyorki DE, Oudit D, Dawson MA, Hicks RJ, Lorigan P, McArthur GA, Marais R, Wong SQ, Dawson SJ. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. *Ann Oncol*. 2019;30:804-814.
41. Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, Risbridger GP. The influence of BRCA2 mutation on localized prostate cancer. *Nat Rev Urol*. 2019;16:281-290.
42. Teh J, Wei J, Chiang G, Nzenza TC, Bolton D, Lawrentschuk N. Men's health on the web: an analysis of current resources. *World Journal of Urology* 2019;37:1043-7.
43. Toss MS, Miligy IM, Haj-Ahmad R, Gorringer KL, AlKawaz A, Mittal K, Ellis IO, Green AR, Rakha EA. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ. *Histopathology* 2019;74:1025-35.
44. Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, Andre F, Bayar MA, Michiels S, Zhang Z, Giorgetti C, Arnedos M, Huang Bartlett C, Cristofanilli M. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. *Journal of Clinical Oncology* 2019;37:1169-78.
45. Wiede F, Brodnicki TC, Goh PK, Leong YA, Jones GW, Yu D, Baxter AG, Jones SA, Kay TWH, Tiganis T. T-Cell-Specific PTPN2 Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune Comorbidities. *Diabetes* 2019;68:1251-66.
46. Wong R, Tie J, Lee M, Cohen J, Wang Y, Li L, Ma S, Christie M, Kosmider S, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. *International Journal of Cancer* 2019;145:540-7.
47. Youens D, Halkett G, Wright C, O'Connor M, Schofield P, Jefford M, Aranda S, Kane R, Moorin R, team RTPp. Assessing the cost-effectiveness of RT Prepare: A radiation therapist-delivered intervention for reducing psychological distress prior to radiotherapy. *Psycho-Oncology* 2019;28:1110-8.
48. Zeinomar N, Phillips KA, Daly MB, Milne RL, Dite GS, MacInnis RJ, Liao Y, Kehm RD, Knight JA, Southey MC, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S, Andrulis IL, Buys SS, John EM, Hopper JL, Terry MB. Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. *International Journal of Cancer* 2019;145:370-9.

June 2019

1. Aslian H, Kron T, Longo F, Rad R, Severgnini M. A review and analysis of stereotactic body radiotherapy and radiosurgery of patients with cardiac implantable electronic devices. *Australasian Physical & Engineering Sciences in Medicine* 2019;42(2):415-25.
2. Baguley BJ, Jefford M, Aly A, Cashin P, White V. Have centralised ethics and governance applications improved the time-variable, and approval process to conduct research in Victorian hospitals? *Internal Medicine Journal* 2019;49(6):807-8.
3. Banting S, Milne D, Thorpe T, Na L, Spillane J, Speakman D, Henderson MA, Gyorki DE. Negative Sentinel Lymph Node Biopsy in Patients with Melanoma: The Patient's Perspective. *Annals of Surgical Oncology* 2019;26(7):2263-7.
4. Beard C, Purvis R, Winship IM, Macrae FA, Buchanan DD. Phenotypic confirmation of oligodontia, colorectal polyposis and cancer in a family carrying an exon 7 nonsense variant in the AXIN2 gene. *Familial Cancer* 2019;18(3):311-5.
5. Bell CC, Fennell KA, Chan YC, Rambow F, Yeung MM, Vassiliadis D, Lara L, Yeh P, Martelotto LG, Rogiers A, Kremer BE, Barbash O, Mohammad HP, Johanson TM, Burr ML, Dhar A, Karpinich N, Tian L, Tyler DS, MacPherson L, Shi J, Pinnawala N, Yew Fong C, Papenfuss AT, Grimmond SM, Dawson SJ, Allan RS, Kruger RG, Vakoc CR, Goode DL, Naik SH, Gilan O, Lam EYN, Marine JC, Prinjha RK, Dawson MA. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. *Nature Communications* 2019;10(1):2723.
6. Binkley MS, Brady JL, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Ahmed S, MacManus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova YM, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Mikhaeel NG, Hoppe RT. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. *International Journal of Radiation Oncology, Biology, Physics* 2019;104(3):522-9.
7. Birkinshaw RW, Gong JN, Luo CS, Lio D, White CA, Anderson MA, Blombery P, Lessene G, Majewski IJ, Thijssen R, Roberts AW, Huang DCS, Colman PM, Czabotar PE. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. *Nature Communications* 2019;10(1):2385.
8. Cloak K, Jameson MG, Paneghel A, Wiltshire K, Kneebone A, Pearse M, Sidhom M, Tang C, Fraser-Browne C, Holloway LC, Haworth A. Contour variation is a primary source of error when delivering post prostatectomy radiotherapy: Results of the Trans-Tasman Radiation Oncology Group 08.03 Radiotherapy Adjuvant Versus Early Salvage (RAVES) benchmarking exercise. *Journal of Medical Imaging and Radiation Oncology* 2019;63(3):390-8.
9. Curchin DJ, Forward E, Dickison P, Harris VR, McCormack CJ, Smith SD. The acceleration of melanoma in situ: A population-based study of melanoma incidence trends from Victoria, Australia, 1985-2015. *J Am Acad Dermatol.* 2019;80(6):1791-3.
10. Deftereos I, Kiss N, Isenring E, Carter V, Yeung JMC. Letter to the Editors regarding: "Preoperative enteral access is not necessary prior to multimodality treatment of esophageal cancer". *Surgery* 2019;166(1):126-7.
11. Dendle C, Polkinghorne KR, Mulley WR, Gan PY, Kanellis J, Stuart RL, Thursky K, Holdsworth SR. A simple score can identify kidney transplant recipients at high risk of severe infection over the following 2 years. *Transplant Infectious Disease* 2019;21(3):e13076.
12. Doyle J, Raggatt M, Slavin M, McLachlan SA, Strasser SI, Sasadeusz JJ, Howell J, Hajkovicz K, Nandurkar H, Johnston A, Bak N, Thompson AJ. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. *Medical Journal of Australia* 2019;210(10):462-8.

13. Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Punwani S, Pond G, Chua S, Ho B, Johnston E, Pouliot F, Scott AM. Prospective, Multisite, International Comparison of ¹⁸F-Fluoromethylcholine PET/CT, Multiparametric MRI, and ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. *Journal of Nuclear Medicine* 2019;60(6):794-800.
14. Fallmann J, Videm P, Bagnacani A, Batut B, Doyle MA, Klingstrom T, Eggenhofer F, Stadler PF, Backofen R, Grüning B. The RNA workbench 2.0: next generation RNA data analysis. *Nucleic Acids Research* 2019;47(W1):W511-5.
15. Gargett M, Haddad C, Kneebone A, Booth JT, Hardcastle N. Clinical impact of removing respiratory motion during liver SABR. *Radiation Oncology* 2019;14(1):93.
16. Hamadi A, Grigg AP, Dobie G, Burbury KL, Schwarzer AP, Kwa FA, Jackson DE. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response. *Thrombosis and Haemostasis* 2019;119(7):1112-23.
17. Hicks RJ, Jackson P, Kong G, Ware RE, Hofman MS, Pattison DA, Akhurst TA, Drummond E, Roselt P, Callahan J, Price R, Jeffery CM, Hong E, Noonan W, Herschtal A, Hicks LJ, Hedt A, Harris M, Paterson BM, Donnelly PS. ⁶⁴Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. *Journal of Nuclear Medicine* 2019;60(6):777-85.
18. Hunter D, Wright C, Pearson S. Employing positive psychology to improve radiation therapy workplace culture. *Journal of Medical Radiation Sciences* 2019;66(2):139-44.
19. Jackson JE, Anderson NJ, Rolfo M, Wada M, Schneider M, Poulsen M, Fahandej M, Huynh A, Lee ST, Joon DL, Khoo V. ¹⁸F-FDG Metabolic Tumor Volume: Association with Short- and Long-Term Feeding Tube Use in Head and Neck IMRT. *Dysphagia* 2019;34(3):341-9.
20. Jamois C, Gibiansky E, Gibiansky L, Buchheit V, Sahin D, Cartron G, Marcus R, Hiddemann W, Seymour JF, Strefford JC, Hargreaves CE, Meneses-Lorente G, Frey N, Fingerle-Rowson G. Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy. *British Journal of Clinical Pharmacology* 2019;85(7):1495-506.
21. Kader T, Hill P, Zethoven M, Goode DL, Elder K, Thio N, Doyle M, Semple T, Sufyan W, Byrne DJ, Pang JB, Murugasu A, Miligy IM, Green AR, Rakha EA, Fox SB, Mann GB, Campbell IG, Gorringer KL. Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. *Journal of Pathology* 2019;248(3):326-38.
22. Kelleher FC, Kroes J, Lewin J. Targeting the centrosome and polo-like kinase 4 in osteosarcoma. *Carcinogenesis* 2019;40(4):493-9.
23. Kilpatrick LE, Alcobia DC, White CW, Peach CJ, Glenn JR, Zimmerman K, Kondrashov A, Pflieger KDG, Ohana RF, Robers MB, Wood KV, Sloan EK, Woolard J, Hill SJ. Complex Formation between VEGFR2 and the beta2-Adrenoceptor. *Cell Chemical Biology* 2019;26(6):830-41.
24. Kron T, Krishnan P. Leonardo DaVinci's contributions to medical physics and biomedical engineering: celebrating the life of a 'Polymath'. *Australasian Physical & Engineering Sciences in Medicine* 2019;42(2):403-5.
25. Lasica M, Willcox A, Burbury K, Ross DM, Branford S, Butler J, Filshie R, Januszewicz H, Joske D, Mills A, Simpson D, Tam C, Taylor K, Watson AM, Wolf M, Grigg A. The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. *Leukemia & Lymphoma* 2019;60(7):1796-802.
26. Le Roux PY, Irvani A, Callahan J, Burbury K, Eu P, Steinfors DP, Lau E, Woon B, Salaun PY, Hicks RJ, Hofman MS. Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: results of the PECAN pilot study. *European Journal of Nuclear Medicine and Molecular Imaging* 2019;46(8):1596-604.

27. Leitinger E, Hui L, Grigg A. Is there a role for proton pump inhibitor prophylaxis in haematology patients? *Internal Medicine Journal* 2019;49(6):694-701.
28. Lippey J, Keogh LA, Mann GB, Campbell IG, Forrest LE. "A Natural Progression": Australian Women's Attitudes About an Individualized Breast Screening Model. *Cancer Prevention Research* 2019;12(6):383-90.
29. Loftus MJ, Yong MK, Wilson S, Peleg AY. Fatal disseminated visceral varicella zoster virus infection in a renal transplant recipient. *Transplant Infectious Disease* 2019;21(3):e13062.
30. Lopez-Perolio I, Leman R, Behar R, Lattimore V, Pearson JF, Castera L, Martins A, Vaur D, Goardon N, Davy G, Garre P, García-Barberán V, Llovet P, Pérez-Segura P, Díaz-Rubio E, Caldés T, Hruska KS, Hsuan V, Wu S, Pesaran T, Karam R, Vallon-Christersson J, Borg A, Investigators K, Valenzuela-Palomo A, Velasco EA, Southey M, Vreeswijk MPG, Devilee P, Kvist A, Spurdle AB, Walker LC, Krieger S, de la Hoya M. Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report. *Journal of Medical Genetics* 2019;56(7):453-60.
31. Mardiana S, Solomon BJ, Darcy PK, Beavis PA. Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. *Science Translational Medicine* 2019;11(495):eaaw2293.
32. Mileshkin L, Edmondson R, O'Connell RL, Sjoquist KM, Andrews J, Jyothirmayi R, Beale P, Bonaventura T, Goh J, Hall M, Clamp A, Green J, Lord R, Amant F, Alexander L, Carty K, Paul J, Scurry J, Millan D, Nottley S, Friedlander M, PARAGON study group. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. *Gynecol Oncol.* 2019;154(1):29-37.
33. Mitchell ML, Shafee T, Papenfuss AT, Norton RS. Evolution of cnidarian trans-defensins: Sequence, structure and exploration of chemical space. *Proteins* 2019;87(7):551-60.
34. Morrow A, Hogden E, Kang YJ, Steinberg J, Canfell K, Solomon MJ, Kench JG, Gill AJ, Shaw T, Pachter N, Parkinson B, Wolfenden L, Mitchell G, Macrae F, Tucker K, Taylor N. Comparing theory and non-theory based implementation approaches to improving referral practices in cancer genetics: a cluster randomised trial protocol. *Trials* 2019;20(1):373.
35. Nan Tie E, Henderson MA, Gyorki DE. Management of in-transit melanoma metastases: a review. *ANZ Journal of Surgery* 2019;89(6):647-52.
36. Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, Goldinger SMA, Smith JL, Everett AS, Koelblinger P, Roberts-Thomson R, Millward M, Atkinson VG, Guminski A, Kapoor R, Conry RM, Carlino MS, Wang W, Shackleton MJ, Eroglu Z, Lo S, Hong AM, Long GV, Johnson DB, Menzies AM. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. *Pigment Cell & Melanoma Research* 2019;32(4):553-63.
37. Porter LH, Lawrence MG, Wang H, Clark AK, Bakshi A, Obinata D, Goode D, Papargiris M, Mural, Clouston D, Ryan A, Norden S, Corey E, Nelson PS, Isaacs JT, Grummet J, Kourambas J, Sandhu S, Murphy DG, Pook D, Frydenberg M, Taylor RA, Risbridger GP. Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. *Prostate* 2019;79(11):1326-37.
38. Remon J, Ahn MJ, Girard N, Johnson M, Kim DW, Lopes G, Pillai RN, Solomon B, Villacampa G, Zhou Q. Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. *Journal of Thoracic Oncology* 2019;14(7):1134-55.
39. Rothe F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. *Clinical Cancer Research* 2019;25(12):3581-8.
40. Schofield P, Shaw T, Pascoe M. Toward Comprehensive Patient-Centric Care by Integrating Digital Health Technology With Direct Clinical Contact in Australia. *Journal of Medical Internet Research* 2019;21(6):e12382.

41. Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. *Haematologica* 2019;104(6):1202-8.
42. Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, Kay NE, Shanafelt TD, Rabe KG, Byrd JC, Chanan-Khan AA, Furman RR, Hillmen P, Jones J, Seymour JF, Sharman JP, Ferrante L, Mobasher M, Stark T, Reddy V, Dreiling LK, Bhargava P, Howes A, James DF, Zelenetz AD. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. *Lancet Haematology* 2019;6(7):e366-74.
43. Stansook N, Biasi G, Utitsarn K, Petasecca M, Metcalfe P, Carolan M, Lerch MLF, Perevertaylo VL, Kron T, Rosenfeld AB. 2D monolithic silicon-diode array detectors in megavoltage photon beams: does the fabrication technology matter? A medical physicist's perspective. *Australasian Physical & Engineering Sciences in Medicine* 2019;42(2):443-51.
44. Teh BW, Chui W, Handunnetti S, Tam C, Worth LJ, Thursky KA, Slavin MA. High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia. *Leukemia & Lymphoma* 2019;60(6):1572-5.
45. Teh J, Narasimhan V, Schultz S, Sathianathen N, Murphy DG. Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *European Urology* 2019;76(1):126-7.
46. Tew M, Clarke P, Thursky K, Dalziel K. Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients. *Pharmacoeconomics* 2019;37(7):931-41.
47. Toivanen R, Furic L. A balancing act: PHLPP2 fine tunes AKT activity and MYC stability in prostate cancer. *Journal of Cell Biology* 2019;218(6):1771-2.
48. Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. *Journal of Clinical Oncology* 2019;37(17):1460-9.
49. Ware RE, Williams S, Hicks RJ. Molecular Imaging of Recurrent and Metastatic Prostate Cancer. *Seminars in Nuclear Medicine*. 2019;49(4):280-93.
50. White VM, Orme LM, Skaczkowski G, Pinkerton R, Coory M, Osborn M, Bibby H, Nicholls W, Conyers R, Phillips MB, Harrup R, Walker R, Thompson K, Anazodo A. Management of Sarcoma in Adolescents and Young Adults: An Australian Population-Based Study. *Journal of Adolescent and Young Adult Oncology* 2019;8(3):272-80.
51. Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. *British Journal Haematology* 2019;186(1):184-8.
52. Xing D, Siva S, Hanna GG. The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado? *Clinical Oncology* 2019;31(7):432-43.
53. Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dreno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, Rooney I, McArthur GA, Ribas A. Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF^{V600}-mutated Metastatic Melanoma. *Clinical Cancer Research* 2019;25(11):3239-46.
54. Young R, Norris B, Reeves F, Peters JS. A Retrospective Comparison of Transrectal and Transperineal Prostate Biopsies: Experience of a Single Surgeon. *Journal of Endourology* 2019;33(6):498-502.

July 2019

1. Bandilovska I, Keam SP, Gamell C, Machicado C, Haupt S, Haupt Y. E6AP goes viral: the role of E6AP in viral- and non-viral-related cancers. *Carcinogenesis* 2019;40:707-14.
2. Beavis PA, Darcy PK. CAR T cells take centre stage. *Clinical & Translational Immunology* 2019;8:e01068.
3. Brighton TA, Khot A, Harrison SJ, Ghez D, Weiss BM, Kirsch A, Magen H, Gironella M, Oriol A, Streetly M, Kranenburg B, Qin X, Bandekar R, Hu P, Guilfoyle M, Qi M, Nemat S, Goldschmidt H. Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma. *Clinical Cancer Research* 2019;25:3772-5.
4. Cameron DL, Di Stefano L, Papenfuss AT. Comprehensive evaluation and characterisation of short read general-purpose structural variant calling software. *Nature Communications* 2019;10:3240.
5. Chait-Rubinek L, Mariani JA, Goroncy N, Herschtal A, Wheeler GC, Dwyer MK, Seymour JF, Campbell BA. A Retrospective Evaluation of Risk of Peripartum Cardiac Dysfunction in Survivors of Childhood, Adolescent and Young Adult Malignancies. *Cancers* 2019;11:1046.
6. Clarebrough E, Duncan C, Christidis D, Lavoipierre A, Lawrentschuk N. PSMA-PET guided hook-wire localization of nodal metastases in prostate cancer: a targeted approach. *World Journal of Urology* 2019;37:1251-4.
7. Cole AJ, Hardcastle N, Turgeon GA, Thomas R, Irving LB, Jennings BR, Ball D, Kron T, Steinfort DP, Siva S. Systematic endobronchial ultrasound-guided transbronchial needle aspiration improves radiotherapy planning in non-small cell lung cancer. *ERJ Open Research* 2019;5:00004-2019.
8. Colebatch AJ, Ferguson P, Newell F, Kazakoff SH, Witkowski T, Dobrovic A, Johansson PA, Saw RPM, Stretch JR, McArthur GA, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Waddell N, Scolyer RA, Wilmott JS. Molecular Genomic Profiling of Melanocytic Nevi. *Journal of Investigative Dermatology* 2019;139:1762-8.
9. Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. *New England Journal of Medicine* 2019;381:121-31.
10. Dieras V, Bonnefoi H, Alba E, Awada A, Coudert B, Pivot X, Gligorov J, Jager A, Zambelli S, Lindeman GJ, Charpentier E, Emmons GT, Garcia-Ribas I, Paridaens R, Verweij J. Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. *Breast Cancer Research and Treatment* 2019;177:383-93.
11. Doolan BJ, Robinson AJ, Wolfe R, Kelly JW, McLean C, McCormack C, Henderson MA, Pan Y. Accuracy of partial biopsies in the management of cutaneous melanoma. *Australasian Journal of Dermatology* 2019;60:209-13.
12. Drosowsky A, Mathieson J, Milne D. Australian Indigenous Communities: Efforts to Improve Cancer Care. *Clinical Journal of Oncology Nursing* 2019;23:443-6.
13. Duncan C, Joon DL, Lawrentschuk N, Jenkins T, Schneider M, Khoo V, Chao M, Lawlor M, O'Meara R, Berry C, Viotto A, Brown K, Wada M, Foroudi F, Sengupta S. Fiducial markers: can the urologist do better? *World Journal of Urology* 2019;37:1281-7.
14. Eapen RS, Nzenza TC, Murphy DG, Hofman MS, Cooperberg M, Lawrentschuk N. PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics. *World Journal of Urology* 2019;37:1255-61.
15. Edbrooke L, Aranda S, Granger CL, McDonald CF, Krishnasamy M, Mileshekin L, Clark RA, Gordon I, Irving L, Denehy L. Multidisciplinary home-based rehabilitation in inoperable lung cancer: a randomised controlled trial. *Thorax* 2019;74:787-96.

16. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Lupinacci R, Krepler C, Ibrahim N, Kicinski M, Marreaud S, van Akkooi AC, Suci S, Robert C. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. *European Journal of Cancer* 2019;116:148-57.
17. ElMokh O, Taelman V, Radojewski P, Roelli MA, Stoss A, Dumont RA, Dettmer MS, Phillips WA, Walter MA, Charles RP. MEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer. *Journal of Nuclear Medicine* 2019;60:917-23.
18. Foulkes SJ, Howden EJ, Bigaran A, Janssens K, Antill Y, Loi S, Claus P, Haykowsky MJ, Daly RM, Fraser SF, A LAG. Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy. *Medicine and Science in Sports and Exercise* 2019;51:1573-81.
19. Goncalves I, Burbury K, Michael M, Irvani A, Ravi Kumar AS, Akhurst T, Tiong IS, Blombery P, Hofman MS, Westerman D, Hicks RJ, Kong G. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. *European Journal of Nuclear Medicine and Molecular Imaging* 2019;46:1902-10.
20. He HJ, Das B, Cleveland MH, Chen L, Camalier CE, Liu LC, Norman KL, Fellowes AP, McEvoy CR, Lund SP, Almeida J, Steffen CR, Karlovich C, Williams PM, Cole KD. Development and interlaboratory evaluation of a NIST Reference Material RM 8366 for EGFR and MET gene copy number measurements. *Clinical Chemistry and Laboratory Medicine* 2019;57:1142-52.
21. Hegi-Johnson F, de Ruyscher D, Keall P, Hendriks L, Vinogradskiy Y, Yamamoto T, Tahir B, Kipritidis J. Imaging of regional ventilation: Is CT ventilation imaging the answer? A systematic review of the validation data. *Radiotherapy and Oncology* 2019;137:175-85.
22. Heriot A, Smart P. Current Status of Segmental Colectomy in Select Crohn's Disease Patients. *Clinics in Colon and Rectal Surgery* 2019;32:249-54.
23. Hilleary LA, Wratten C, Siva S, Hilleary J, Martin JM. Intratumoural renal cell carcinoma haemorrhage following stereotactic radiotherapy: a case report. *BMC Cancer* 2019;19:671.
24. Ho PJ, Moore EM, McQuilten ZK, Wellard C, Bergin K, Augustson B, Blacklock H, Harrison SJ, Horvath N, King T, Mollee P, Quach H, Reid C, Rosengarten B, Walker P, Wood EM, Spencer A. Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. *Clinical Lymphoma, Myeloma & Leukemia* 2019;19:e415-e424.
25. Irvani A, Turgeon GA, Akhurst T, Callahan JW, Bressel M, Everitt SJ, Siva S, Hofman MS, Hicks RJ, Ball DL, Mac Manus MP. PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment. *European Journal of Nuclear Medicine and Molecular Imaging* 2019;46:1869-77.
26. Jiang W, Withers B, Sutrave G, Clancy LE, Yong MI, Blyth E. Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus. *Current Hematologic Malignancy Reports* 2019;14:247-60.
27. Khaleel S, Sathianathen N, Balaji P, Dahm P. Quality of urological systematic reviews registered in PROSPERO. *BJU International* 2019;124:195-6.
28. Khot A, Brajanovski N, Cameron DP, Hein N, Maclachlan KH, Sanij E, Lim J, Soong J, Link E, Blombery P, Thompson ER, Fellowes A, Sheppard KE, McArthur GA, Pearson RB, Hannan RD, Poortinga G, Harrison SJ. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. *Cancer Discovery* 2019;9:1036-49.

29. Khoueiry P, Ward Gahlawat A, Petretich M, Michon AM, Simola D, Lam E, Furlong EE, Benes V, Dawson MA, Prinjha RK, Drewes G, Grandi P. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity. *Epigenetics Chromatin* 2019;12:39.
30. Kiser K, Meheissen MAM, Mohamed ASR, Kamal M, Ng SP, Elhalawani H, Jethanandani A, He R, Ding Y, Rostom Y, Hegazy N, Bahig H, Garden A, Lai S, Phan J, Gunn GB, Rosenthal D, Frank S, Brock KK, Wang J, Fuller CD. Prospective quantitative quality assurance and deformation estimation of MRI-CT image registration in simulation of head and neck radiotherapy patients. *Clin Transl Radiat Oncol* 2019;18:120-7.
31. Kleftogiannis D, Punta M, Jayaram A, Sandhu S, Wong SQ, Gasi Tandefelt D, Conteduca V, Wetterskog D, Attard G, Lise S. Identification of single nucleotide variants using position-specific error estimation in deep sequencing data. *BMC Medical Genomics* 2019;12:115.
32. Kondrashova O, Scott CL. Clarifying the role of EMSY in DNA repair in ovarian cancer. *Cancer* 2019;125:2720-4.
33. Konvinse KC, Trubiano JA, Pavlos R, James I, Shaffer CM, Bejan CA, Schutte RJ, Ostrov DA, Pilkinton MA, Rosenbach M, Zwerner JP, Williams KB, Bourke J, Martinez P, Rwandamuriye F, Chopra A, Watson M, Redwood AJ, White KD, Mallal SA, Phillips EJ. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. *Journal of Allergy and Clinical Immunology* 2019;144:183-92.
34. Lai-Kwon J, Khoo C, Lo S, Milne D, Mohamed M, Raleigh J, Smith K, Lisy K, Sandhu S, Jefford M. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. *Journal of Cancer Survivorship* 2019;13:503-11.
35. Lambertini M, Campbell C, Gelber RD, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart M, Loi S, de Azambuja E. Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. *Breast Cancer Research and Treatment* 2019;177:103-14.
36. Lamkin DM, Srivastava S, Bradshaw KP, Betz JE, Muy KB, Wiese AM, Yee SK, Waggoner RM, Arevalo JMG, Yoon AJ, Faull KF, Sloan EK, Cole SW. C/EBPbeta regulates the M2 transcriptome in beta-adrenergic-stimulated macrophages. *Brain, Behavior, and Immunity* 2019;80:839-48.
37. Lasocki A, Phillips KA, Drummond K, Caspersz L. Unexpected diagnosis of spinal leptomeningeal metastatic disease on MRI myelography. *Journal of Clinical Neuroscience* 2019;66:259-61.
38. Lee HC, Md Yusof HH, Leong MP, Zainal Abidin S, Seth EA, Hewitt CA, Vidyadaran S, Nordin N, Scott HS, Cheah PS, Ling KH. Gene and protein expression profiles of JAK-STAT signalling pathway in the developing brain of the Ts1Cje down syndrome mouse model. *International Journal of Neuroscience* 2019;129:871-81.
39. Lefevre C, Venkat P, Kumar A, Modepalli V, Nicholas KR. Comparative analysis of milk microRNA in the therian lineage highlights the evolution of lactation. *Reproduction, Fertility and Development* 2019;31:1266-1275.
40. Leung SCY, Nielsen TO, Zabaglo LA, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Ehinger A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hugh JC, Kos Z, Laenkholm AV, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Sugie T, van der Vegt B, Viale G, Hayes DF, McShane LM, Dowsett M. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. *Histopathology* 2019;75:225-35.
41. Lewis K, Hauschild A, Larkin J, Ribas A, Flaherty KT, McArthur GA, Dreno B, McKenna E, Zhu Q, Mun Y, Ascierto PA. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival

in patients with BRAF^{V600} mutation-positive metastatic melanoma treated with vemurafenib +/- cobimetinib. *European Journal of Cancer* 2019;116:45-55.

42. Loft M, Lee B, Tie J, Gibbs P. Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma. *J Pers Med* 2019;9:37.
43. Ludmir EB, Mahajan A, Ahern V, Ajithkumar T, Alapetite C, Bernier-Chastagner V, Bindra RS, Bishop AJ, Bolle S, Brown PD, Carrie C, Chalmers AJ, Chang EL, Chung C, Dieckmann K, Esiashvili N, Gandola L, Ghia AJ, Gondi V, Grosshans DR, Harrabi SB, Horan G, Indelicato DJ, Jalali R, Janssens GO, Krause M, Laack NN, Laperriere N, Laprie A, Li J, Marcus KJ, McGovern SL, Merchant TE, Merrell KW, Padovani L, Parkes J, Paulino AC, Schwarz R, Shih HA, Souhami L, Sulman EP, Taylor RE, Thorp N, Timmermann B, Wheeler G, Wolden SL, Woodhouse KD, Yeboa DN, Yock TI, Kortmann RD, McAleer MF. Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. *Nature Reviews Clinical Oncology* 2019;16:521-2.
44. McKenzie MD, Ghisi M, Oxley EP, Ngo S, Cimmino L, Esnault C, Liu R, Salmon JM, Bell CC, Ahmed N, Erlichster M, Witkowski MT, Liu GJ, Chopin M, Dakic A, Simankowicz E, Pomilio G, Vu T, Krsmanovic P, Su S, Tian L, Baldwin TM, Zalcenstein DA, DiRago L, Wang S, Metcalf D, Johnstone RW, Croker BA, Lancaster GI, Murphy AJ, Naik SH, Nutt SL, Pospisil V, Schroeder T, Wall M, Dawson MA, Wei AH, de The H, Ritchie ME, Zuber J, Dickins RA. Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. *Cell Stem Cell* 2019;25:258-72.
45. Miura JT, Kroon HM, Beasley GM, Mullen D, Farrow NE, Mosca PJ, Lowe MC, Farley CR, Kim Y, Naqvi SMH, Potdar A, Daou H, Sun J, Farma JM, Henderson MA, Speakman D, Serpell J, Delman KA, Smithers BM, Coventry BJ, Tyler DS, Thompson JF, Zager JS. Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. *Annals of Surgical Oncology* 2019;26:2486-94.
46. Nguyen EV, Pereira BA, Lawrence MG, Ma X, Rebello RJ, Chan H, Niranjan B, Wu Y, Ellem S, Guan X, Wu J, Skhinas JN, Cox TR, Risbridger GP, Taylor RA, Lister NL, Daly RJ. Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment. *Molecular & Cellular Proteomics* 2019;18:1410-27.
47. Oertlin C, Lorent J, Murie C, Furic L, Topisirovic I, Larsson O. Generally applicable transcriptome-wide analysis of translation using anota2seq. *Nucleic Acids Research* 2019;47:e70.
48. Pascoe MC, Parker AG. Physical activity and exercise as a universal depression prevention in young people: A narrative review. *Early Interv Psychiatry* 2019;13:733-9.
49. Philip J, Collins A, Ritchie D, Le B, Millar J, McLachlan SA, Krishnasamy M, Hudson P, Sundararajan V. Patterns of end-of-life hospital care for patients with non-Hodgkin lymphoma: exploring the landscape. *Leukemia and Lymphoma* 2019;60:1908-16.
50. Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Ahmed M, Aittomaki K, Andrulis IL, Arnold N, Arun BK, Ausems M, Azzollini J, Barrowdale D, Barwell J, Benitez J, Bialkowska K, Bonadona V, Borde J, Borg A, Bradbury AR, Brunet J, Buys SS, Caldes T, Caligo MA, Campbell I, Carter J, Chiquette J, Chung WK, Claes KBM, Collee JM, Collonge-Rame MA, Couch FJ, Daly MB, Delnatte C, Diez O, Domchek SM, Dorfling CM, Eason J, Easton DF, Eeles R, Engel C, Evans DG, Faivre L, Feliubadalo L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Gehrig A, Glendon G, Godwin AK, Gomez Garcia EB, Hamann U, Hauke J, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, Janavicius R, John EM, Karlan BY, Kets CM, Laitman Y, Lazaro C, Leroux D, Lester J, Lesueur F, Loud JT, Lubinski J, Lukomska A, McGuffog L, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Mouret-Fourme E, Nathanson KL, Nehoray B, Neuhausen SL, Nevanlinna H, Nielsen FC, Offit K, Olah E, Ong KR, Oosterwijk JC, Ottini L, Parsons MT, Peterlongo P, Pfeiler G, Pradhan N, Radice P, Ramus SJ, Rantala J, Rennert G, Robson M, Rodriguez GC, Salani R, Scheuner MT, Schmutzler RK, Shah PD, Side LE, Simard J, Singer CF, Steinemann D, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Terry MB, Thomassen M, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Venat-Bouvet L, Vierstraete J, Wagner G, Walker L,

Weitzel JN, Yannoukakos D, Antoniou AC, Goldgar DE, Olopade OI, Chenevix-Trench G, Rebbeck TR, Huo D. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer* 2019;121:180-92.

51. Qu LG, Teh J, Mitchell C, Gyorki DE, Hicks RJ, Murphy DG. Characterizing high-grade serous papillary carcinoma of tunica vaginalis. *Urol Case Rep* 2019;26:100949.
52. Rasmussen V, Forbes Shepherd R, Forrest LE, James PA, Young MA. Men's experiences of recontact about a potential increased risk of prostate cancer due to Lynch Syndrome: "Just another straw on the stack". *J Genet Couns* 2019;28:750-9.
53. Ren J, Yang W, Su J, Ren X, Fazelzad R, Albert T, Habbous S, Goldstein DP, de Almeida JR, Hansen A, Jang R, Bratman SV, Hope A, Chen R, Wang J, Xu Y, Cheng D, Zhao Y, Xu W, Liu G. Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region. *International Journal of Cancer* 2019;145:1465-74.
54. Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. *Blood* 2019;134:111-22.
55. Rosenthal M, Curry R, Reardon DA, Rasmussen E, Upreti VV, Damore MA, Henary HA, Hill JS, Cloughesy T. Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. *Cancer Chemotherapy and Pharmacology* 2019;84:327-36.
56. Ross DM, Pagani IS, Irani YD, Clarson J, Leclercq T, Dang P, McLean J, Saunders VA, Carne L, Reynolds J, Ritchie DS, White DL, Branford S, Hughes TP, Yong ASM. Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. *British Journal of Haematology* 2019;186:e56-e60.
57. Roviello G, Corona SP, Multari AG, Petrioli R, Rosellini P, Aieta M. Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel. *Anti-Cancer Drugs* 2019;30:e0789.
58. Ruhle A, Andratschke N, Siva S, Guckenberger M. Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma? *Clin Transl Radiat Oncol* 2019;18:104-12.
59. Shawky MS, Huo CW, Henderson MA, Redfern A, Britt K, Thompson EW. A review of the influence of mammographic density on breast cancer clinical and pathological phenotype. *Breast Cancer Research and Treatment* 2019;177:251-76.
60. Srivastava R, Cao Z, Nedeva C, Naim S, Bachmann D, Rabachini T, Gangoda L, Shahi S, Glab J, Menassa J, Osellame L, Nelson T, Fernandez-Marrero Y, Brown F, Wei A, Ke F, O'Reilly L, Doerflinger M, Allison C, Kueh A, Ramsay R, Smith BJ, Mathivanan S, Kaufmann T, Puthalakath H. BCL-2 family protein BOK is a positive regulator of uridine metabolism in mammals. *Proceedings of the National Academy of Sciences of the United States of America* 2019;116:15469-74.
61. Sun Y, Reynolds HM, Wraith D, Williams S, Finnegan ME, Mitchell C, Murphy D, Haworth A. Automatic stratification of prostate tumour aggressiveness using multiparametric MRI: a horizontal comparison of texture features. *Acta Oncologica* 2019;58:1118-26.
62. Taieb D, Hicks RJ, Hindie E, Guillet BA, Avram A, Ghedini P, Timmers HJ, Scott AT, Elojeimy S, Rubello D, Virgolini IJ, Fanti S, Balogova S, Pandit-Taskar N, Pacak K. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. *European Journal of Nuclear Medicine and Molecular Imaging* 2019;46:2112-37.
63. Tajaldeen A, Ramachandran P, Alghamdi S, Geso M. On the use of AAA and AcurosXB algorithms for three different stereotactic ablative body radiotherapy (SABR) techniques: Volumetric modulated arc

therapy (VMAT), intensity modulated radiation therapy (IMRT) and 3D conformal radiotherapy (3D-CRT). *Rep Pract Oncol Radiother* 2019;24:399-408.

64. Takenaka M, Kobel M, Garsed DW, Fereday S, Pandey A, Etemadmoghadam D, Hendley J, Kawabata A, Noguchi D, Yanaihara N, Takahashi H, Kiyokawa T, Ikegami M, Takano H, Isonishi S, Ochiai K, Traficante N, Gadipally S, Semple T, Vassiliadis D, Amarasinghe K, Li J, Mir Arnau G, Okamoto A, Friedlander M, Bowtell DDL. Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. *Clinical Cancer Research* 2019;25:3962-73.
65. Teh BW, Chui W, Handunnetti S, Tam C, Worth LJ, Thursky KA, Slavin MA. High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia. *Leukemia and Lymphoma* 2019;60:1572-5.
66. Thangasamy IA, Alghazo O, Murphy DG. Are we ready to adopt the European Association of Urology recommendations on multiparametric magnetic resonance imaging in the early detection of prostate cancer? *Investig Clin Urol* 2019;60:225-6.
67. Tutty E, Petelin L, McKinley J, Young MA, Meiser B, Rasmussen VM, Forbes Shepherd R, James PA, Forrest LE. Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer. *European Journal of Human Genetics* 2019;27:1186-96.
68. Udovicich C, Phillips C, Kok DL, Tange D, Plumridge NM, Prabhu RS, Haghghi N. Neoadjuvant Stereotactic Radiosurgery: a Further Evolution in the Management of Brain Metastases. *Current Oncology Reports* 2019;21:73.
69. Ugalde A, Blaschke S, Boltong A, Schofield P, Aranda S, Phipps-Nelson J, Chambers SK, Krishnasamy M, Livingston PM. Understanding rural caregivers' experiences of cancer care when accessing metropolitan cancer services: a qualitative study. *BMJ Open* 2019;9:e028315.
70. Wei AH, Roberts AW. Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia? *Cancer Discovery* 2019;9:998-1000.
71. Weinberg L, Ianno D, Churilov L, McGuigan S, Mackley L, Banting J, Shen SH, Riedel B, Nikfarjam M, Christophi C. Goal directed fluid therapy for major liver resection: A multicentre randomized controlled trial. *Ann Med Surg* 2019;45:45-53.
72. Wong Doo N, White VM, Martin K, Bassett JK, Prince HM, Harrison SJ, Jefford M, Winship I, Millar JL, Milne RL, Seymour JF, Giles GG. The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment. *Cancers* 2019;11:928.
73. Xing D, Siva S, Hanna GG. The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado? *Clinical Oncology* 2019;31:432-43.
74. Yonis G, Cabalag CS, Link E, Duong CP. Utility of routine oral contrast study for detecting postesophagectomy anastomotic leak - a systematic review and meta-analysis. *Diseases of the Esophagus* 2019;32:doz011.
75. Zhang X, Tang JZ, Vergara IA, Zhang Y, Szeto P, Yang L, Mintoff C, Colebatch A, McIntosh L, Mitchell KA, Shaw E, Rizos H, Long GV, Hayward N, McArthur GA, Papenfuss AT, Harvey KF, Shackleton M. Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma. *Molecular Cancer Research* 2019;17:1435-49.

August 2019

1. Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. *Annals of Oncology* 2019;30:405-11.

2. Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortes J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. *Annals of Oncology* 2019;30:397-404.
3. Anderson L, Goh MS, McCormack CJ. Scalp BCC's and meningioma following X-ray epilation for tinea capitis. *Australasian Journal of Dermatology* 2019;60:149-50.
4. Bachem A, Makhoul C, Binger KJ, de Souza DP, Tull D, Hochheiser K, Whitney PG, Fernandez-Ruiz D, Dahling S, Kastenmuller W, Jonsson J, Gressier E, Lew AM, Perdomo C, Kupz A, Figgett W, Mackay F, Oleshansky M, Russ BE, Parish IA, Kallies A, McConville MJ, Turner SJ, Gebhardt T, Bedoui S. Microbiota-Derived Short-Chain Fatty Acids Promote the Memory Potential of Antigen-Activated CD8+ T Cells. *Immunity* 2019;51:285-97.
5. Baker EJ, Waters PS, Peacock O, McCormick JJ, Heriot AG, Warriar SK. Advanced Application of TaTME Platform For a T4 Anterior Rectal Tumor. *Surgical Laparoscopy, Endoscopy & Percutaneous Techniques* 2019;29:e45-9.
6. Barker HE, Scott CL. Preclinical rare cancer research to inform clinical trial design. *Nature Reviews Cancer* 2019;19:481-2.
7. Brockwell NK, Rautela J, Owen KL, Gearing LJ, Deb S, Harvey K, Spurling A, Zanker D, Chan CL, Cumming HE, Deng N, Zakhour JM, Duivenvoorden HM, Robinson T, Harris M, White M, Fox J, Ooi C, Kumar B, Thomson J, Potasz N, Swarbrick A, Hertzog PJ, Molloy TJ, O'Toole SA, Ganju V, Parker BS. Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. *Precision Oncology* 2019;3:21.
8. Cao L, Basudan A, Sikora MJ, Bahreini A, Tasdemir N, Levine KM, Jankowitz RC, McAuliffe PF, Dabbs D, Haupt S, Haupt Y, Lucas PC, Lee AV, Oesterreich S, Atkinson JM. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. *Cancer Letters* 2019;461:21-30.
9. Chann AS, Russell SM. An integrated transcriptional switch at the beta-selection checkpoint determines T cell survival, development and leukaemogenesis. *Biochemical Society Transactions* 2019;47:1077-89.
10. Clarebrough E, Christidis D, Lindner U, Fernandes K, Fleshner N, Lawrentschuk N. Analysis of a practical surgical skills laboratory for nerve sparing radical prostatectomy. *World Journal of Urology* 2019;37:799-804.
11. Collins A, Sundararajan V, Millar J, Burchell J, Le B, Krishnasamy M, McLachlan SA, Hudson P, Mileskin L, Philip J. The trajectory of patients who die from metastatic prostate cancer: a population-based study. *BJU International* 2019;123(Suppl 5):19-26.
12. De Abreu Lourenco R, Williams S. Health Technology Assessment and Health Care Utilisation in the Management of Early Prostate Cancer. *European Urology Focus* 2019;5:134-6.
13. Douglas AP, Thursky KA, Worth LJ, Harrison SJ, Hicks RJ, Slavin MA. Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists. *Internal Medicine Journal* 2019;49:615-21.
14. Edbrooke L, Granger CL, Clark RA, Denehy L. Physical Activity Levels Are Low in Inoperable Lung Cancer: Exploratory Analyses from a Randomised Controlled Trial. *Journal of Clinical Medicine* 2019;8:1288.
15. Fischer F, Helmer S, Rogge A, Arraras JI, Buchholz A, Hannawa A, Horneber M, Kiss A, Rose M, Sollner W, Stein B, Weis J, Schofield P, Witt CM. Outcomes and outcome measures used in evaluation of communication training in oncology - a systematic literature review, an expert workshop, and recommendations for future research. *BMC Cancer* 2019;19:808.

16. Forsyth CJ, Chan WH, Grigg AP, Cook NC, Lane SW, Burbury KL, Perkins AC, Ross DM. Recommendations for the use of pegylated Interferon- α in the treatment of classical myeloproliferative neoplasms. *Internal Medicine Journal* 2019;49:948-954.
17. Gately L, Wong HL, Tie J, Wong R, Lee M, Lee B, Jalali A, Gibbs P. Emerging strategies in the initial management of locally advanced rectal cancer. *Future Oncology* 2019;15:2955-65.
18. Goel S, Liu J, Guo H, Barry W, Bell R, Murray B, Lynch J, Bastick P, Chantrill L, Kiely BE, Abdi E, Rutovitz J, Asghari R, Sullivan A, Harrison M, Kohonen-Corish M, Beith J. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. *JACC Heart Failure* 2019;7:795-804.
19. Grant DJ, Manichaikul A, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Funkhouser E, Moorman PG, Peres LC, Peters ES, Schwartz AG, Terry PD, Wang XQ, Keku TO, Hoyo C, Berchuck A, Sandler DP, Taylor JA, O'Brien KM, Velez Edwards DR, Edwards TL, Beeghly-Fadiel A, Wentzensen N, Pearce CL, Wu AH, Whittemore AS, McGuire V, Sieh W, Rothstein JH, Modugno F, Ness R, Moysich K, Rossing MA, Doherty JA, Sellers TA, Permuth-Way JB, Monteiro AN, Levine DA, Setiawan VW, Haiman CA, LeMarchand L, Wilkens LR, Karlan BY, Menon U, Ramus S, Gayther S, Gentry-Maharaj A, Terry KL, Cramer DW, Goode EL, Larson MC, Kaufmann SH, Cannioto R, Odunsi K, Etter JL, Huang RY, Bernardini MQ, Tone AA, May T, Goodman MT, Thompson PJ, Carney ME, Tworoger SS, Poole EM, Lambrechts D, Vergote I, Vanderstichele A, Van Nieuwenhuysen E, Anton-Culver H, Ziogas A, Brenton JD, Bjorge L, Salvensen HB, Kiemeny LA, Massuger L, Pejovic T, Bruegl A, Moffitt M, Cook L, Le ND, Brooks-Wilson A, Kelemen LE, Pharoah PDP, Song H, Campbell I, Eccles D, DeFazio A, Kennedy CJ, Schildkraut JM. Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. *Cancer Medicine* 2019;8:2503-13.
20. Grimm L, Nakajima H, Chaudhury S, Bower NI, Okuda KS, Cox AG, Harvey NL, Koltowska K, Mochizuki N, Hogan BM. Yap1 promotes sprouting and proliferation of lymphatic progenitors downstream of Vegfc in the zebrafish trunk. *Elife* 2019;8:e42881.
21. Howard MD, Sim S. A Novel Association between Antiretroviral Therapy and Drug-Induced Immune Thrombocytopenia Purpura. *Acta Haematologica* 2019;141:199-200.
22. Jamrozik E, Selgelid MJ. Surveillance and control of asymptomatic carriers of drug-resistant bacteria. *Bioethics* 2019;33:766-75.
23. Khot A. Where do we currently stand with T-cell prolymphocytic leukemia? *Leukemia and Lymphoma* 2019;60:563-5.
24. Kong G, Hicks RJ. Peptide Receptor Radiotherapy: Current Approaches and Future Directions. *Current Treatment Options in Oncology* 2019;20:77.
25. Lasocki A, Gaillard F. Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research. *AJNR American Journal of Neuroradiology* 2019;40:758-65.
26. Lasocki A, Hicks RJ. How we read: the combined use of MRI and novel PET tracers for the characterisation and treatment planning of masses in neuro-oncology. *Cancer Imaging* 2019;19:57.
27. Lomax AJ, McQuillan PIA, Hall A, McArthur GA. Acute toxic epidermal necrolysis reaction post single dose pembrolizumab with preceding cephalosporin exposure: successful rechallenge with anti-PD-1 therapy. *Internal Medicine Journal* 2019;49:1051-1053.
28. Lotfi-Jam K, Gough K, Schofield P, Aranda S, Jefford M. A longitudinal study of four unique trajectories of psychological distress in cancer survivors after completing potentially curative treatment. *Acta Oncologica* 2019;58:782-9.
29. Martin J, Keall P, Siva S, Greer P, Christie D, Moore K, Dowling J, Pryor D, Chong P, McLeod N, Raman A, Lynam J, Smart J, Oldmeadow C, Tang CI, Murphy DG, Millar J, Tai KH, Holloway L, Reeves P, Hayden A, Lim T, Holt T, Sidhom M. TROG 18.01 phase III randomised clinical trial of the Novel Integration of New

prostate radiation schedules with adjuvant Androgen deprivation: NINJA study protocol. *BMJ Open* 2019;9:e030731.

30. Mileskin L, Dunn C, Cross H, Duffy M, Shaw M, Antippa P, Mitchell P, Akhurst T, Conron M, Moore M, Philip J, Bartlett J, Emery J, Zambello B. The Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia. *Internal Medicine Journal* 2019;49:1001-6.
31. Mohammad AH, Assadian S, Couture F, Lefebvre KJ, El-Assaad W, Barres V, Ouellet V, Boulay PL, Yang J, Latour M, Furic L, Muller W, Sonenberg N, Mes-Masson AM, Saad F, Day R, Teodoro JG. V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss. *Oncotarget* 2019;10:4923-36.
32. Murphy DG, Padhani AR, Ost P. Adding Colour to the Grey Zone of Advanced Prostate Cancer. *European Urology Focus* 2019;5:123-4.
33. Nagpal A, Redvers RP, Ling X, Ayton S, Fuentes M, Tavancheh E, Diala I, Lalani A, Loi S, David S, Anderson RL, Smith Y, Merino D, Denoyer D, Pouliot N. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2⁺ breast cancer metastasis. *Breast Cancer Research* 2019;21:94.
34. Norris J, Barker J, Buelens O, Spruijt O. Does continuous subcutaneous infusion of lignocaine relieve intractable pruritus associated with advanced cutaneous T-cell lymphoma? A retrospective case series review. *Palliative Medicine* 2019;33:552-6.
35. Ong WL, Bailey E, McCormack C, Weston L, Morgan V, McDowell L. Definitive radiotherapy for Merkel cell carcinoma in the setting of epidermolysis bullosa simplex. *Australasian Journal of Dermatology* 2019;60:153-4.
36. Oon SF, Singh D, Tan TH, Lee A, Noe G, Burbury K, Paiva J. Primary myelofibrosis: spectrum of imaging features and disease-related complications. *Insights Imaging* 2019;10:71.
37. Ramchandra R, Xing DT, Matear M, Lambert G, Allen AM, May CN. Neurohumoral interactions contributing to renal vasoconstriction and decreased renal blood flow in heart failure. *American Journal of Physiology Regulatory, Integrative and Comparative Physiology* 2019;317:R386-96.
38. Ranasinghe WKB, Williams S, Ischia J, Wetherell D, Baldwin G, Shulkes A, Sengupta S, Bolton D, Patel O. Metformin may offer no protective effect in men undergoing external beam radiation therapy for prostate cancer. *BJU International* 2019;123(Suppl 5):36-42.
39. Ribí K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Muller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J. Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. *British Journal of Cancer* 2019;120:959-67.
40. Seidel D, Meissner A, Lackner M, Piepenbrock E, Salmanton-Garcia J, Stecher M, Mellinghoff S, Hamprecht A, Duran Graeff L, Kohler P, Cheng MP, Denis J, Chedotal I, Chander J, Pakstis DL, Los-Arcos I, Slavin M, Montagna MT, Caggiano G, Mares M, Trauth J, Aurbach U, Vehreschild M, Vehreschild JJ, Duarte RF, Herbrecht R, Wisplinghoff H, Cornely OA. Prognostic factors in 264 adults with invasive *Scedosporium* spp. and *Lomentospora prolificans* infection reported in the literature and FungiScope(R). *Critical Reviews in Microbiology* 2019;45:1-21.
41. Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martin-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. *Lancet* 2019;394:478-87.

42. Teoh B, Waters PS, Peacock O, Smart P, Reid K, Rajkumar A, Heriot AG, Warriar SK. Utilising taTME and robotics to reduce R1 risk in locally advanced rectal cancer with rectovaginal and cervical involvement. *Techniques in Coloproctology* 2019;23:387-90.
43. Vogrin AJ, Bower NI, Gunzburg MJ, Roufail S, Okuda KS, Paterson S, Headey SJ, Stacker SA, Hogan BM, Achen MG. Evolutionary Differences in the Vegf/Vegfr Code Reveal Organotypic Roles for the Endothelial Cell Receptor Kdr in Developmental Lymphangiogenesis. *Cell Reports* 2019;28:2023-36.
44. Wang SS, Kotecha RS, Bernard A, Blyth CC, McMullan BJ, Cann MP, Yeoh DK, Bartlett AW, Ryan AL, Moore AS, Bryant PA, Clark J, Haeusler GM. Invasive fungal infections in children with acute lymphoblastic leukaemia: Results from four Australian centres, 2003-2013. *Pediatric Blood & Cancer* 2019;66:e27915.
45. Zhao K, Bleackley M, Chisanga D, Gangoda L, Fonseka P, Liem M, Kalra H, Al Saffar H, Keerthikumar S, Ang CS, Adda CG, Jiang L, Yap K, Poon IK, Lock P, Bulone V, Anderson M, Mathivanan S. Extracellular vesicles secreted by *Saccharomyces cerevisiae* are involved in cell wall remodelling. *Communications Biology* 2019;2:305.

September 2019

1. AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, Slater A, Ardley K, Kirby L, Chan KT, Brajanovski N, Smith LK, Rao AD, Lelliott EJ, Kleinschmidt M, Vergara IA, Papenfuss AT, Lau P, Ghosh P, Haupt S, Haupt Y, Sanij E, Poortinga G, Pearson RB, Falk H, Curtis DJ, Stuppel P, Devlin M, Street I, Davies MA, McArthur GA, Sheppard KE. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. *Proceedings of the National Academy of Sciences of the United States of America* 2019;116:17990-8000.
2. Alghazo O, Thangasamy I, Sathianathan N, Murphy DG. Re: Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer. *European Urology* 2019;76:536-7.
3. Campbell BA, Plastaras JP, Savage KJ. Keeping Our Finger on the Pulse: Reaffirming the Role of Radiation Therapy in the Curative Management of Early Stage Follicular Lymphoma. *International Journal of Radiation Oncology, Biology, Physics* 2019;105:459-65.
4. Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Böhm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew YE, Churchman M, DeFazio A, Demeo R, Dudley R, Fairweather N, Fedele CG, Fereday S, Fox SB, Gilks CB, Gourley C, Hacker NF, Hadley AM, Hendley J, Ho GY, Hughes S, Hunstman DG, Hunter SM, Jobling TW, Kalli KR, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Mes-Masson AM, Mileskin L, Provencher DM, Pyman J, Rahimi K, Rowley SM, Salazar C, Samimi G, Saunders H, Semple T, Sharma R, Sharpe AJ, Stephens AN, Thio N, Torres MC, Traficante N, Xing Z, Zethoven M, Antill YC, Scott CL, Campbell IG, Goringe KL. The molecular origin and taxonomy of mucinous ovarian carcinoma. *Nature Communications* 2019;10:3935.
5. Chiu SK, Orive SL, Moon MJ, Saw J, Ellis S, Kile BT, Huang Y, Chacon D, Pimanda JE, Beck D, Hamilton JR, Tremblay CS, Curtis DJ. Shared roles for Scl and Lyl1 in murine platelet production and function. *Blood* 2019;134:826-35.
6. Devchand M, Stewardson AJ, Urbancic KF, Khumra S, Mahony AA, Walker S, Garrett K, Grayson ML, Trubiano JA. Outcomes of an electronic medical record (EMR)-driven intensive care unit (ICU)-antimicrobial stewardship (AMS) ward round: Assessing the "Five Moments of Antimicrobial Prescribing". *Infection Control and Hospital Epidemiology* 2019;40:1170-5.
7. Dodd GT, Xirouchaki CE, Eramo M, Mitchell CA, Andrews ZB, Henry BA, Cowley MA, Tiganis T. Intranasal Targeting of Hypothalamic PTP1B and TCPTP Reinstates Leptin and Insulin Sensitivity and Promotes Weight Loss in Obesity. *Cell Reports* 2019;28:2905-22.

8. Freeman AJ, Vervoort SJ, Ramsbottom KM, Kelly MJ, Michie J, Pijpers L, Johnstone RW, Kearney CJ, Oliaro J. Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion. *Cell Reports* 2019;28:2784-94.
9. Ge C, Huang H, Huang F, Yang T, Zhang T, Wu H, Zhou H, Chen Q, Shi Y, Sun Y, Liu L, Wang X, Pearson RB, Cao Y, Kang J, Fu C. Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload. *Proceedings of the National Academy of Sciences of the United States of America* 2019;116:19635-45.
10. Hardcastle N, Hofman MS, Lee CY, Callahan J, Selbie L, Foroudi F, Shaw M, Chander S, Lim A, Chesson B, Murphy DG, Kron T, Siva S. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy. *Radiation Oncology* 2019;14:164.
11. Hofman MS, Emmett L. Tumour Heterogeneity and Resistance to Therapy in Prostate Cancer: A Fundamental Limitation of Prostate-specific Membrane Antigen Theranostics or a Key Strength? *European Urology* 2019;76:479-81.
12. Konert T, Vogel WV, Paez D, Polo A, Fidarova E, Carvalho H, Duarte PS, Zuliani AC, Santos AO, Altuhhova D, Karusoo L, Kapoor R, Sood A, Khader J, Al-Ibraheem A, Numair Y, Abubaker S, Soydal C, Kutuk T, Le TA, Canh NX, Bieu BQ, Ha LN, Belderbos JSA, MacManus MP, Thorwarth D, Hanna GG. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial. *European Journal of Nuclear Medicine and Molecular Imaging* 2019;46:2235-43.
13. Kong G, Schenberg T, Yates CJ, Trainer A, Sachithanandan N, Iravani A, Ravi Kumar A, Hofman MS, Akhurst T, Michael M, Hicks RJ. The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma. *Journal of Clinical Endocrinology and Metabolism* 2019;104:5091-9.
14. Koulis A, Buckle A, Boussioutas A. Premalignant lesions and gastric cancer: Current understanding. *World Journal of Gastrointestinal Oncology* 2019;11:665-78.
15. Lee AW, Ng WT, Pan JJ, Chiang CL, Poh SS, Choi HC, Ahn YC, AlHussain H, Corry J, Grau C, Gregoire V, Harrington KJ, Hu CS, Kwong DL, Langendijk JA, Le QT, Lee NY, Lin JC, Lu TX, Mendenhall WM, O'Sullivan B, Ozyar E, Peters LJ, Rosenthal DI, Sanguineti G, Soong YL, Tao Y, Yom SS, Wee JT. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. *International Journal of Radiation Oncology, Biology, Physics* 2019;105:567-80.
16. Lewin J, Desai J, Smith K, Luen S, Wong D. Lack of clinical activity with crizotinib in a patient with FUS rearranged rhabdomyosarcoma with ALK protein overexpression. *Pathology* 2019;51:655-7.
17. McKenzie MG, Cobbs LV, Dummer PD, Petros TJ, Halford MM, Stacker SA, Zou Y, Fishell GJ, Au E. Non-canonical Wnt Signaling through Ryk Regulates the Generation of Somatostatin- and Parvalbumin-Expressing Cortical Interneurons. *Neuron* 2019;103:853-64.
18. Michalak EM, Burr ML, Bannister AJ, Dawson MA. The roles of DNA, RNA and histone methylation in ageing and cancer. *Nature Reviews Molecular Cell Biology* 2019;20:573-89.
19. Minshall C, Pascoe MC, Thompson DR, Castle DJ, McCabe M, Chau JPC, Jenkins Z, Cameron J, Ski CF. Psychosocial interventions for stroke survivors, carers and survivor-carer dyads: a systematic review and meta-analysis. *Topics in Stroke Rehabilitation* 2019;26:554-64.
20. Narasimhan V, Britto M, Pham T, Warriar S, Naik A, Lynch AC, Michael M, Tie J, Ramsay R, Heriot A. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience. *Diseases of the Colon and Rectum* 2019;62:1195-203.
21. Nissim S, Leshchiner I, Mancias JD, Greenblatt MB, Maertens O, Cassa CA, Rosenfeld JA, Cox AG, Hedgepeth J, Wucherpfennig JI, Kim AJ, Henderson JE, Gonyo P, Brandt A, Lorimer E, Unger B, Prokop JW, Heidel JR, Wang XX, Ukaegbu CI, Jennings BC, Paulo JA, Gableske S, Fierke CA, Getz G, Sunyaev SR,

- Wade Harper J, Cichowski K, Kimmelman AC, Houvras Y, Syngal S, Williams C, Goessling W. Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. *Nature Genetics* 2019;51:1308-14.
22. Pang SS, Bayly-Jones C, Radjainia M, Spicer BA, Law RHP, Hodel AW, Parsons ES, Ekel SM, Conroy PJ, Ramm G, Venugopal H, Bird PI, Hoogenboom BW, Voskoboinik I, Gambin Y, Sierecki E, Dunstone MA, Whisstock JC. The cryo-EM structure of the acid activatable pore-forming immune effector Macrophage-expressed gene 1. *Nature Communications* 2019;10:4288.
 23. Puelles VG, van der Wolde JW, Wanner N, Scheppach MW, Cullen-McEwen LA, Bork T, Lindenmeyer MT, Gernhold L, Wong MN, Braun F, Cohen CD, Kett MM, Kuppe C, Kramann R, Saritas T, van Roeyen CR, Moeller MJ, Tribolet L, Rebello R, Sun YB, Li J, Muller-Newen G, Hughson MD, Hoy WE, Person F, Wiech T, Ricardo SD, Kerr PG, Denton KM, Furic L, Huber TB, Nikolic-Paterson DJ, Bertram JF. mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans. *JCI Insight* 2019;4:e99271.
 24. Semene L, Vergara IA, Laloo AE, Mathews ER, Bond PL, Franks AE. Enhanced Growth of Pilin-Deficient *Geobacter sulfurreducens* Mutants in Carbon Poor and Electron Donor Limiting Conditions. *Microbial Ecology* 2019;78:618-30.
 25. Shirokikh NE, Dutikova YS, Staroverova MA, Hannan RD, Preiss T. Migration of small ribosomal subunits on the 5' untranslated regions of capped messenger RNA. *International Journal of Medical Sciences* 2019;20:4464.
 26. Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. *Blood* 2019;134:851-9.
 27. Tang M, O'Connell RL, Amant F, Beale P, McNally O, Sjoquist KM, Grant P, Davis A, Sykes P, Mileskin L, Moujaber T, Kennedy CJ, deFazio A, Tan K, Antill Y, Goh J, Bonaventura T, Scurry J, Friedlander M. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. *Gynecologic Oncology* 2019;154:531-8.
 28. Taylor RA, Watt MJ. Unsuspected Protumorigenic Signaling Role for the Oncometabolite GABA in Advanced Prostate Cancer. *Cancer Research* 2019;79:4580-1.
 29. Toss MS, Miligy IM, Gorringer KL, Aleskandarany MA, Alkawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Rakha EA. Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ. *Modern Pathology* 2019;32:1460-72.
 30. Toss MS, Miligy IM, Gorringer KL, Alkawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Roxanis I, Rakha EA. Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study. *Modern Pathology* 2019;32:1473-85.
 31. Tower H, Ruppert M, Britt K. The Immune Microenvironment of Breast Cancer Progression. *Cancers* 2019;11:1375.
 32. Trubiano JA, Slavin MA, Thursky KA, Grayson ML, Phillips EJ. Beta-Lactam and Sulfonamide Allergy Testing Should Be a Standard of Care in Immunocompromised Hosts. *Journal of Allergy and Clinical Immunology: In Practice* 2019;7:2151-3.
 33. Woodhouse B, Pattison S, Segelov E, Singh S, Parker K, Kong G, Macdonald W, Wyld D, Meyer-Rochow G, Pavlakis N, Conroy S, Gordon V, Koea J, Kramer N, Michael M, Wakelin K, Asif T, Lo D, Price T, Lawrence B. Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care. *Journal of Clinical Medicine* 2019;8:1455.
 34. Zaorsky NG, Lehrer EJ, Kothari G, Louie AV, Siva S. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. *European Urology Oncology* 2019;2:515-23.

35. Zhang L, Bao Y, Riaz M, Tiller J, Liew D, Zhuang X, Amor DJ, Huq A, Petelin L, Nelson M, James PA, Winship I, McNeil JJ, Lacaze P. Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis. *Genetics in Medicine* 2019;21:1958-68.

October 2019

1. Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, Shaw AT. Clinical Management of Adverse Events Associated with Lorlatinib. *Oncologist* 2019;24:1103-10.
2. Bell SW, Heriot AG, Warriar SK, Farmer CK, Stevenson ARL, Bissett I, Kong JC, Solomon M. Surgical techniques in the management of rectal cancer: a modified Delphi method by colorectal surgeons in Australia and New Zealand. *Techniques in Coloproctology* 2019;23:743-9.
3. Berger I, Thompson K, Joubert L. An Exploratory Study into the Experience of Health Care Professionals Caring for Adolescents and Young Adults with Incurable Cancer. *Journal of Adolescent and Young Adult Oncology* 2019;8:458-62.
4. Blombery P, Birkinshaw RW, Nguyen T, Gong JN, Thompson ER, Xu Z, Westerman DA, Czabotar PE, Dickinson M, Huang DCS, Seymour JF, Roberts AW. Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. *British Journal of Haematology* 2019;186:e188-91.
5. Bodelon C, Killian JK, Sampson JN, Anderson WF, Matsuno R, Brinton LA, Lissowska J, Anglesio MS, Bowtell DDL, Doherty JA, Ramus SJ, Talhouk A, Sherman ME, Wentzensen N. Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity. *Clinical Cancer Research* 2019;25:5937-46.
6. Bucknell NW, Dixon BJ, Hoffman MS, McDowell LJ. Importance of timing in staging head and neck cancer: cervical adenopathy post-tonsillectomy mimicking malignancy. *ANZ Journal of Surgery* 2019;89:1167-9.
7. Burr ML, Sparbier CE, Chan KL, Chan YC, Kersbergen A, Lam EYN, Azidis-Yates E, Vassiliadis D, Bell CC, Gilan O, Jackson S, Tan L, Wong SQ, Hollizeck S, Michalak EM, Siddle HV, McCabe MT, Prinjha RK, Guerra GR, Solomon BJ, Sandhu S, Dawson SJ, Beavis PA, Tothill RW, Cullinane C, Lehner PJ, Sutherland KD, Dawson MA. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. *Cancer Cell* 2019;36:385-401.
8. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Fendler WP, Czernin J. What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply. *Lancet Oncology* 2019;20:e609-10.
9. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. ¹⁸F-fluciclovine PET-CT and ⁶⁸Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. *Lancet Oncology* 2019;20:1286-94.
10. Campbell BA, Hofman MS, Prince HM. A Novel Application of [¹⁸F]Fluorothymidine-PET ([¹⁸F]FLT-PET) in Clinical Practice to Quantify Regional Bone Marrow Function in a Patient With Treatment-Induced Cytopenias and to Guide "Marrow-Sparing" Radiotherapy. *Clinical Nuclear Medicine* 2019;44:e624-6.
11. Casswell G, Cavanagh K, Ravi Kumar AS, Giddings C, McDowell L. Setting the stage: Contemporary staging of non-melanomatous skin cancer and implementation of the new American Joint Committee on cancer eighth edition staging manual. *Oral Oncology* 2019;98:102-8.
12. Charnley M, Ludford-Menting M, Pham K, Russell SM. A new role for Notch in the control of polarity and asymmetric cell division of developing T cells. *Journal of Cell Science* 2019;133:jcs235358.

13. Christiansen D, Mouhtouris E, Hodgson R, Sutton VR, Trapani JA, Ierino FL, Sandrin MS. Antigen-specific CD4+ CD25+ T cells induced by locally expressed ICOS-Ig: the role of Foxp3, Perforin, Granzyme B and IL-10 - an experimental study. *Transplant International* 2019;32:1203-15.
14. Craike M, Bourke M, Hilland TA, Wiesner G, Pascoe MC, Bengoechea EG, Parker AG. Correlates of Physical Activity Among Disadvantaged Groups: A Systematic Review. *American Journal of Preventive Medicine* 2019;57:700-15.
15. de Boer SM, Powell ME, Mileskin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jurgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit V, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL, Group PS. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. *Lancet Oncology* 2019;20:1273-85.
16. Doidge O, Edwards N, Thompson K, Lewin J. A Conceptual Framework to Identify and Address the Education and Vocational Barriers Experienced by Adolescents and Young Adults with Cancer. *Journal of Adolescent and Young Adult Oncology* 2019;8:398-401.
17. Dunn A, Johnstone RW, Stillman B. Joseph F. Sambrook (1939-2019). *Nature Structural & Molecular Biology* 2019;26:846-7.
18. Esposito D, Weile J, Shendure J, Starita LM, Papenfuss AT, Roth FP, Fowler DM, Rubin AF. MaveDB: an open-source platform to distribute and interpret data from multiplexed assays of variant effect. *Genome Biology* 2019;20:223.
19. Gao C, McCormack C, van der Weyden C, Goh MS, Campbell BA, Twigger R, Buelens O, Harrison SJ, Khoo C, Lade S, Prince HM. Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sezary syndrome. *Blood* 2019;134:1346-50.
20. Goel S, Tolaney SM. CDK4/6 inhibitors in breast cancer: a role in triple-negative disease? *Lancet Oncology* 2019;20:1479-81.
21. Grech LB, Butler E, Stuckey S, Hester R. Letter to the editor: FLOUX-PMS study sample considerations. *Multiple Sclerosis* 2019;25:1819-20.
22. Green EM, Blunck Y, Tahayori B, Farrell PM, Korte JC, Johnston LA. Spin Lock Adiabatic Correction (SLAC) for B1-insensitive pulse design at 7T. *Journal of Magnetic Resonance* 2019;308:106595.
23. Hanna B, Ranasinghe W, Lawrentschuk N. Risk stratification and avoiding overtreatment in localized prostate cancer. *Current Opinion in Urology* 2019;29:612-9.
24. Hasmat S, Ebrahimi A, Luk PP, Low TH, McDowell L, Magarey MJR, Veness M, Gupta R, Clark J. Positive survival trend in metastatic head and neck cutaneous squamous cell carcinoma over four-decades: Multicenter study. *Head and Neck* 2019;41:3826-32.
25. Hellmann MD, Kim TW, Lee CB, Goh BC, Miller WH, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang YJ, Siu LL, Bendell J. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. *Annals of Oncology* 2019;30:1134-42.
26. Hewson EA, Nguyen DT, O'Brien R, Kim JH, Montanaro T, Moodie T, Greer PB, Hardcastle N, Eade T, Kneebone A, Hruby G, Hayden AJ, Turner S, Siva S, Tai KH, Hunter P, Sams J, Poulsen PR, Booth JT, Martin J, Keall PJ. The accuracy and precision of the KIM motion monitoring system used in the multi-institutional TROG 15.01 Stereotactic Prostate Ablative Radiotherapy with KIM (SPARK) trial. *Medical Physics* 2019;46:4725-37.
27. Holt NR, Downey G, Naughton MT. Perioperative considerations in the management of obstructive sleep apnoea. *Medical Journal of Australia* 2019;211:326-32.

28. Ierano C, Thursky K, Marshall C, Koning S, James R, Johnson S, Imam N, Worth LJ, Peel T. Appropriateness of Surgical Antimicrobial Prophylaxis Practices in Australia. *JAMA Network Open* 2019;2:e1915003.
29. Kapoor J, Koschel S, Murphy DG. Editorial Comment. *Journal of Urology* 2019;202:1180-1.
30. Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. *New England Journal of Medicine* 2019;381:1632-43.
31. Koschel S, Murphy DG, Hofman MS, Wong LM. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer. *Current Opinion in Urology* 2019;29:569-77.
32. Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schoder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. EANM procedure guidelines for radionuclide therapy with ¹⁷⁷Lu-labelled PSMA-ligands (¹⁷⁷Lu-PSMA-RLT). *European Journal of Nuclear Medicine and Molecular Imaging* 2019;46:2536-44.
33. Laitman Y, Friebel TM, Yannoukakos D, Fostira F, Konstantopoulou I, Figlioli G, Bonanni B, Manoukian S, Zuradelli M, Tondini C, Pasini B, Peterlongo P, Plaseska-Karanfilska D, Jakimovska M, Majidzadeh K, Zarinfam S, Loizidou MA, Hadjisavvas A, Michailidou K, Kyriacou K, Behar DM, Molho RB, Ganz P, James P, Parsons MT, Sallam A, Olopade OI, Seth A, Chenevix-Trench G, Leslie G, McGuffog L, Marafie MJ, Megarbane A, Al-Mulla F, Rebbeck TR, Friedman E. The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. *Human Mutation* 2019;40:e1-e23.
34. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Marquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schoffski P, Carlino MS, Lebbe C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *New England Journal of Medicine* 2019;381:1535-46.
35. Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA, Dreno B, Yan Y, Wongchenko M, McKenna E, Zhu Q, Mun Y, Hauschild A. Impact of depth of response on survival in patients treated with cobimetinib +/- vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. *British Journal of Cancer* 2019;121:522-8.
36. Licqurish SM, Cook OY, Pattuwage LP, Saunders C, Jefford M, Koczwara B, Johnson CE, Emery JD. Tools to facilitate communication during physician-patient consultations in cancer care: An overview of systematic reviews. *CA: A Cancer Journal for Clinicians* 2019;69:497-520.
37. Lindsay J, Teh BW, Micklethwaite K, Slavin M. Azole antifungals and new targeted therapies for hematological malignancy. *Current Opinion in Infectious Diseases* 2019;32:538-45.
38. Lisy K, Langdon L, Piper A, Jefford M. Identifying the most prevalent unmet needs of cancer survivors in Australia: A systematic review. *Asia Pacific Journal of Clinical Oncology* 2019;15:e68-e78.
39. Metser U, Chua S, Ho B, Punwani S, Johnston E, Pouliot F, Tau N, Hawsaway A, Anconina R, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Pond G, Scott AM, Tunariu N, Sidhu H, Emmett L. The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of ¹⁸F-Fluoromethylcholine or ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. *Journal of Nuclear Medicine* 2019;60:1253-8.
40. Miles LF, Burbury KL, Story DA. Selecting and optimising patients for total knee arthroplasty. *Medical Journal of Australia* 2019;211:285.

41. Morris TA, Khoo C, Solomon BJ. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors. *Drugs* 2019;79:1277-86.
42. Murphy DG, Hofman MS, Azad A, Violet J, Hicks RJ, Lawrentschuk N. Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. *BJU International* 2019;124:551-553.
43. Narasimhan V, Das A, Warriar S, Lynch C, McCormick J, Tie J, Michael M, Ramsay R, Heriot A. Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases. *Langenbeck's Archives of Surgery* 2019;404:527-39.
44. Narasimhan V, Pham T, Warriar S, Craig Lynch A, Michael M, Tie J, Ramsay R, Heriot A. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms. *ANZ Journal of Surgery* 2019;89:1035-40.
45. Ng ZY, Bishton M, Ritchie D, Campbell R, Gilbertson M, Hill K, Ratnasingam S, Schwarer A, Manos K, Shorten S, Ng M, Nelson N, Xin L, De Mel Widanalage S, Sunny T, Purtill D, Poon M, Johnston A, Cochrane T, Lee HP, Hapgood G, Tam C, Opat S, Hawkes E, Seymour J, Cheah CY. A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. *Hematological Oncology* 2019;37:253-60.
46. Nones K, Johnson J, Newell F, Patch AM, Thorne H, Kazakoff SH, de Luca XM, Parsons MT, Ferguson K, Reid LE, McCart Reed AE, Srihari S, Lakis V, Davidson AL, Mukhopadhyay P, Holmes O, Xu Q, Wood S, Leonard C, Kathleen Cuninghame Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab), Australian Breast Cancer Tissue Bank (ABCTB), Brisbane Breast Bank (BBB), Beesley J, Harris JM, Barnes D, Degasperi A, Ragan MA, Spurdle AB, Khanna KK, Lakhani SR, Pearson JV, Nik-Zainal S, Chenevix-Trench G, Waddell N, Simpson PT. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers. *Annals of Oncology* 2019;30:1071-9.
47. O'Leary B, Hrebien S, Beaney M, Fribbens C, Garcia-Murillas I, Jiang J, Li Y, Huang Bartlett C, Andre F, Loibl S, Loi S, Cristofanilli M, Turner NC. Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. *Clinical Chemistry* 2019;65:1405-13.
48. Osborn M, Johnson R, Thompson K, Anazodo A, Albritton K, Ferrari A, Stark D. Models of care for adolescent and young adult cancer programs. *Pediatric Blood & Cancer* 2019;66:e27991.
49. Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadalo L, Aalfs CM, Agata S, Aittomaki K, Alducci E, Alonso-Cerezo MC, Arnold N, Auber B, Austin R, Azzollini J, Balmana J, Barbieri E, Bartram CR, Blanco A, Blumcke B, Bonache S, Bonanni B, Borg A, Bortesi B, Brunet J, Bruzzone C, Bucksch K, Cagnoli G, Caldes T, Caliebe A, Caligo MA, Calvello M, Capone GL, Caputo SM, Carnevali I, Carrasco E, Caux-Moncoutier V, Cavalli P, Cini G, Clarke EM, Concolino P, Cops EJ, Cortesi L, Couch FJ, Darder E, de la Hoya M, Dean M, Debatin I, Del Valle J, Delnatte C, Derive N, Diez O, Ditsch N, Domchek SM, Dutrannoy V, Eccles DM, Ehrencrona H, Enders U, Evans DG, Farra C, Faust U, Felbor U, Feroce I, Fine M, Foulkes WD, Galvao HCR, Gambino G, Gehrig A, Gensini F, Gerdes AM, Germani A, Giesecke J, Gismondi V, Gomez C, Gomez Garcia EB, Gonzalez S, Grau E, Grill S, Gross E, Guerrieri-Gonzaga A, Guillaud-Bataille M, Gutierrez-Enriquez S, Haaf T, Hackmann K, Hansen TVO, Harris M, Hauke J, Heinrich T, Hellebrand H, Herold KN, Honisch E, Horvath J, Houdayer C, Hubbel V, Iglesias S, Izquierdo A, James PA, Janssen LAM, Jeschke U, Kaulfuss S, Keupp K, Kiechle M, Kolbl A, Krieger S, Kruse TA, Kvist A, Laloo F, Larsen M, Lattimore VL, Lautrup C, Ledig S, Leinert E, Lewis AL, Lim J, Loeffler M, Lopez-Fernandez A, Lucci-Cordisco E, Maass N, Manoukian S, Marabelli M, Matricardi L, Meindl A, Michelli RD, Moghadasi S, Moles-Fernandez A, Montagna M, Montalban G, Monteiro AN, Montes E, Mori L, Moserle L, Muller CR, Mundhenke C, Naldi N, Nathanson KL, Navarro M, Nevanlinna H, Nichols CB, Niederacher D, Nielsen HR, Ong KR, Pachter N, Palmero EI, Papi L, Pedersen IS, Peissel B, Perez-Segura P, Pfeifer K, Pineda M, Pohl-Rescigno E, Poplawski NK, Porfirio B, Quante AS, Ramser J, Reis RM, Revillion F, Rhiem K, Riboli B, Ritter J, Rivera D, Rofes P, Rump A, Salinas M, Sanchez de Abajo AM, Schmidt G, Schoenwiese U, Seggewiss J, Solanes A, Steinemann D, Stiller M, Stoppa-Lyonnet D, Sullivan KJ, Susman R, Sutter C, Tavitgian SV, Teo SH, Teule A, Thomassen M, Tibiletti MG, Tischkowitz M,

- Tognazzo S, Toland AE, Tornero E, Torngren T, Torres-Esquius S, Toss A, Trainer AH, Tucker KM, van Asperen CJ, van Mackelenbergh MT, Varesco L, Vargas-Parra G, Varon R, Vega A, Velasco A, Vesper AS, Viel A, Vreeswijk MPG, Wagner SA, Waha A, Walker LC, Walters RJ, Wang-Gohrke S, Weber BHF, Weichert W, Wieland K, Wiesmuller L, Witzel I, Wockel A, Woodward ER, Zachariae S, Zampiga V, Zeder-Goss C, Investigators K, Lazaro C, De Nicolo A, Radice P, Engel C, Schmutzler RK, Goldgar DE, Spurdle AB. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. *Human Mutation* 2019;40:1557-78.
50. Peacock O, Waters PS, Bressel M, Lynch AC, Wakeman C, Eglinton T, Koh CE, Lee PJ, Austin KK, Warriar SK, Solomon MJ, Frizelle FA, Heriot AG. Prognostic factors and patterns of failure after surgery for T4 rectal cancer in the beyond total mesorectal excision era. *British Journal of Surgery* 2019;106:1685-96.
 51. Pham T, Pereira L, Roth S, Galletta L, Link E, Akhurst T, Solomon B, Michael M, Darcy P, Sampurno S, Heriot A, Ramsay R, Desai J. First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427). *Contemp Clin Trials Commun* 2019;16:100409.
 52. Rahbar K, Hofman MS, Schrader AJ, Bogemann M. A Self-Fulfilling Prophecy: Comparing 177Lu-PSMA Radioligand Therapy in Taxane-Naive Versus Posttaxane Metastasized Prostate Cancer Patients? *Journal of Nuclear Medicine* 2019;60:1494.
 53. Sharma VJ, Gupta A, Yaftian N, Ball D, Brown R, Barnett S, Antippa P. Low recurrence of lung adenoid cystic carcinoma with radiotherapy and resection. *ANZ Journal of Surgery* 2019;89:1051-5.
 54. Shaw AT, Riely GJ, Bang YJ, Kim DW, Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI, Usari T, Wang SC, Wilner KD, Clark JW, Ou SI. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. *Annals of Oncology* 2019;30:1121-6.
 55. Sheppard KE, AbuHammad S. CDK4/6 inhibition in cancer: the cell cycle splicing connection. *Molecular & Cellular Oncology* 2019;6:e1673643.
 56. Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, Bholra PD, Ryan J, Guerriero JL, Montero J, Liang FJ, Cherniack AD, Piccioni F, Matulonis UA, Bowtell DDL, Sarosiek KA, Letai A, Garraway LA, Johannessen CM, Meyerson M. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. *Molecular Cancer Research* 2019;17:2281-93.
 57. Talwelkar SS, Nagaraj AS, Devlin JR, Hemmes A, Potdar S, Kiss EA, Saharinen P, Salmenkivi K, Mayranpaa MI, Wennerberg K, Verschuren EW. Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras-Mutant Lung Cancers. *Molecular Cancer Therapeutics* 2019;18:1863-74.
 58. Thijssen R, Roberts AW. Venetoclax in Lymphoid Malignancies: New Insights, More to Learn. *Cancer Cell* 2019;36:341-3.
 59. Tino R, Leary M, Yeo A, Brandt M, Kron T. Gyroid structures for 3D-printed heterogeneous radiotherapy phantoms. *Physics in Medicine and Biology* 2019;64:21NT05.
 60. Tobin JWD, Rule G, Colvin K, Calvente L, Hodgson D, Bell S, Dunduru C, Gallo J, Tsang ES, Tan X, Wong J, Pearce J, Campbell R, Tneh S, Shorten S, Ng M, Cochrane T, Tam CS, Abro E, Hawkes E, Hodges G, Kansara R, Talaulikar D, Gilbertson M, Johnston AM, Savage KJ, Villa D, Morris K, Ratnasingam S, Janowski W, Kridel R, Cheah CY, MacManus M, Matigian N, Mollee P, Gandhi MK, Hapgood G. Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. *Blood Advances* 2019;3:2804-11.
 61. Toppi J, Webb A. Locally recurrent lentigo maligna within a skin graft: a case report. *ANZ Journal of Surgery* 2019;89:1161-2.

62. Utitsarn K, Biasi G, Stansook N, Alrowaili ZA, Petasecca M, Carolan M, Perevertaylo VL, Tome WA, Kron T, Lerch MLF, Rosenfeld AB. Two-dimensional solid-state array detectors: A technique for in vivo dose verification in a variable effective area. *Journal of Applied Clinical Medical Physics* 2019;20:88-94.
63. Vodanovich DA, Spelman T, May D, Slavin J, Choong PFM. Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases. *ANZ Journal of Surgery* 2019;89:1045-50.
64. Zia NA, Cullinane C, Van Zuylekom JK, Waldeck K, McInnes LE, Buncic G, Haskali MB, Roselt PD, Hicks RJ, Donnelly PS. A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention. *Angewandte Chemie* 2019;58:14991-4.

November 2019

1. Adler N, McArthur GA, Mar VJ. Lymphatic and hematogenous dissemination in patients with primary cutaneous melanoma. *JAMA Dermatology* 2019;115:1322.
2. Ahn SH, Yeo AU, Kim KH, Kim C, Goh Y, Cho S, Lee SB, Lim YK, Kim H, Shin D, Kim T, Kim TH, Youn SH, Oh ES, Jeong JH. Comparative clinical evaluation of atlas and deep-learning-based auto-segmentation of organ structures in liver cancer. *Radiation Oncology* 2019;14:213.
3. Bergin ART, Luen SJ, Savas P, Boolell V, Cho D, Lynch J, Nott L, Stuart-Harris R, Teo LN, Yap SY, Loi S. Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series. *Asia-Pacific Journal of Clinical Oncology* 2019;15:377-82.
4. Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, Jr., Psyrrri A, Baste N, Neupane P, Bratland A, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, Gonzalez Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet* 2019;394:1915-28.
5. Butcher G, Howard H, Sathianathen N, Catto JWF, Murphy DG. Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. *European Urology* 2019;76:872-3.
6. Campbell BA, Ryan G, McCormack C, Tangas E, Bressel M, Twigger R, Buelens O, van der Weyden C, Prince HM. Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides. *Cancers* 2019;11:e1758.
7. Chen Z, Wang H, D'Souza C, Koay HF, Meehan B, Zhao Z, Pediongco T, Shi M, Zhu T, Wang B, Kjer-Nielsen L, Eckle SBG, Rossjohn J, Fairlie DP, Godfrey DI, Strugnell RA, McCluskey J, Corbett AJ. Characterization and Purification of Mouse Mucosal-Associated Invariant T (MAIT) Cells. *Current Protocols in Immunology* 2019;127:e89.
8. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-Leon DE, Drgona L, Groll AH, Guinea J, Heussel CP, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee DG, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadiis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild M, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. *Lancet Infectious Diseases* 2019;19:e405-21.

9. De Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, Van As N, Siva S, Fodor A, Dirix P, Gomez-Iturriaga A, Trippa F, Detti B, Ingrosso G, Triggiani L, Bruni A, Alongi F, Reynders D, De Meerleer G, Surgo A, Loukili K, Miralbell R, Silva P, Chander S, Di Muzio NG, Maranzano E, Francolini G, Lancia A, Tree A, Deantoni CL, Ponti E, Marvaso G, Goetghebeur E, Ost P. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. *European Urology* 2019;76:732-9.
10. Fennell KA, Bell CC, Dawson MA. Epigenetic therapies in acute myeloid leukemia: where to from here? *Blood* 2019;134:1891-901.
11. Haupt S, Caramia F, Herschtal A, Soussi T, Lozano G, Chen H, Liang H, Speed TP, Haupt Y. Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network. *Nature Communications* 2019;10:5385.
12. Henderson MA, Gyorki D, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, Hong A, Shannon K, Scolyer RA, Carruthers S, Coventry BJ, Babington S, Duprat J, Hoekstra HJ, Thompson JF. Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life. *Annals of Surgical Oncology* 2019;26:4663-72.
13. Hilton-Proctor JP, Ilyichova O, Zheng Z, Jennings IG, Johnstone RW, Shortt J, Mountford SJ, Scanlon MJ, Thompson PE. Synthesis and elaboration of N-methylpyrrolidone as an acetamide fragment substitute in bromodomain inhibition. *Bioorganic & Medicinal Chemistry* 2019;27:115157.
14. Ierano C, Thursky K, Peel T, Rajkhowa A, Marshall C, Ayton D. Influences on surgical antimicrobial prophylaxis decision making by surgical craft groups, anaesthetists, pharmacists and nurses in public and private hospitals. *PLoS One* 2019;14:e0225011.
15. Koh J, Walsh P, D'Costa I, Bhatti O. Head and neck squamous cell carcinoma survivorship care. *Australian Journal of General Practice* 2019;48:846-8.
16. Loveday BPT, Lipton L, Thomson BN. Pancreatic cancer: An update on diagnosis and management. *Australian Journal of General Practice* 2019;48:826-31.
17. Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, El-Bahrawy MA, Ness RB, Odunsi K, Steed H, Herpel E, Anglesio MS, Zhang B, Lambie N, Swerdlow AJ, Lubinski J, Vierkant RA, Goode EL, Menon U, Toloczko-Grabarek A, Oszurek O, Bilic S, Talhouk A, Garcia-Closas M, Wang Q, Tan A, Farrell R, Kennedy CJ, Jimenez-Linan M, Sundfeldt K, Etter JL, Menkiszak J, Goodman MT, Klonowski P, Leung Y, Winham SJ, Moysich KB, Behrens S, Kluz T, Edwards RP, Gronwald J, Modugno F, Hernandez BY, Chow C, Kelemen LE, Keeney GL, Carney ME, Natanzon Y, Robertson G, Sharma R, Gayther SA, Alsop J, Luk H, Karpinskyj C, Campbell I, Sinn P, Gentry-Maharaj A, Coulson P, Chang-Claude J, Shah M, Widschwendter M, Tang K, Schoemaker MJ, Koziak JM, Cook LS, Brenton JD, Daley F, Kristjansdottir B, Mateoiu C, Larson MC, Harnett PR, Jung A, deFazio A, Gorringer KL, Pharoah PDP, Minoo P, Stewart C, Bathe OF, Gui X, Cohen P, Ramus SJ, Kobel M. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. *Modern Pathology* 2019;32:1834-46.
18. Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. *American Journal of Hematology* 2019;94:1353-63.
19. Nan Tie E, Na LH, Hicks RJ, Spillane J, Speakman D, Henderson MA, Gyorki DE. The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre. *Annals of Surgical Oncology* 2019;26:4673-80.
20. Olafson LR, Siddell AH, Field KM, Byrnes M, Rapkins RW, Ng B, Nixdorf S, Barnes EH, Johns TG, Yip S, Simes J, Nowak AK, Rosenthal MA, McDonald KL. Whole genome and biomarker analysis of patients

with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial. *Journal of Clinical Neuroscience* 2019;70:157-63.

21. Oliver AJ, Davey AS, Keam SP, Mardiana S, Chan JD, von Scheidt B, Beavis PA, House IG, Van Audernaerde JR, Darcy PK, Kershaw MH, Slaney CY. Tissue-specific tumor microenvironments influence responses to immunotherapies. *Clinical & Translational Immunology* 2019;8:e1094.
22. Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeny LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadalo L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems M, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MWG, Helder van den Enden A, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon YCT, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Ronlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrone K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. *European Urology* 2019;76:831-42.
23. Paige E, Thursky K, Slavin M. Mold-active prophylaxis in acute leukemia: not enough of a good thing? *Leukemia and Lymphoma* 2019;60:2851-3.
24. Partap S, Russo S, Esfahani B, Yeom K, Mazewski C, Embry L, Wheeler G, Ullrich NJ, Bowers DC. A Review of Chronic Leukoencephalopathy among Survivors of Childhood Cancer. *Pediatric Neurology* 2019;101:2-10.
25. Pascoe M, Ski CF, Thompson DR, Linden T. Serum cholesterol, body mass index and smoking status do not predict long-term cognitive impairment in elderly stroke patients. *Journal of the Neurological Sciences* 2019;406:116476.
26. Pavlakis N, Cooper C, John T, Kao S, Klebe S, Lee CK, Leong T, Millward M, O'Byrne K, Russell PA, Solomon B, Cooper WA, Fox S. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. *Pathology* 2019;51:673-80.
27. Peacock O, Waters PS, Otero de Pablos J, Boussioutas A, Skandarajah A, Simpson JA, Warriar SK, Heriot AG. A systematic review of risk-reducing cancer surgery outcomes for hereditary cancer syndromes. *European Journal of Surgical Oncology* 2019;45:2241-50.
28. Rudd-Schmidt JA, Hodel AW, Noori T, Lopez JA, Cho HJ, Verschoor S, Ciccone A, Trapani JA, Hoogenboom BW, Voskoboinik I. Lipid order and charge protect killer T cells from accidental death. *Nature Communications* 2019;10:5396.
29. Sun Y, Williams S, Byrne D, Keam S, Reynolds HM, Mitchell C, Wraith D, Murphy D, Haworth A. Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: a pilot study. *British Journal of Radiology* 2019;92:20190373.
30. Tam CS, Siddiqi T, Allan JN, Kipps TJ, Flinn IW, Kuss BJ, Opat S, Barr PM, Tedeschi A, Jacobs R, Badoux XC, Ghia P, Sukbuntherng J, Salem AH, Russell K, Eckert K, Zhou C, Ninomoto J, James DF, Wierda WG. Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. *Blood* 2019;134:35.

31. Vardy JL, Chan RJ, Koczwara B, Lisy K, Cohn RJ, Joske D, Dhillon HM, Jefford M. Clinical Oncology Society of Australia position statement on cancer survivorship care. *Australian Journal of General Practice* 2019;48:833-6.
32. Waters PS, Peacock O, Warriar SK, Wakeman C, Eglinton T, Lynch AC, Frizelle FA, Heriot AG, McCormick J. Evolution of pelvic exenteration surgery- resectional trends and survival outcomes over three decades. *European Journal of Surgical Oncology* 2019;45:2325-33.
33. Zeinomar N, Knight JA, Genkinger JM, Phillips KA, Daly MB, Milne RL, Dite GS, Kehm RD, Liao Y, Southey MC, Chung WK, Giles GG, McLachlan SA, Friedlander ML, Weideman PC, Glendon G, Nesci S, Andrulis IL, Buys SS, John EM, MacInnis RJ, Hopper JL, Terry MB. Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (Prof-SC). *Breast Cancer Research* 2019;21:128.

December 2019

1. Allen ML, Leslie K, Parker AV, Kim CC, Brooks SL, Braat S, Schug SA, Story DA. Post-surgical opioid stewardship programs across Australia and New Zealand: Current situation and future directions. *Anaesthesia and Intensive Care* 2019;47:548-52.
2. Anderson NJ, Jackson JE, Wada M, Schneider M, Poulsen M, Rolfo M, Fahandej M, Gan H, Khoo V. The changing landscape of head and neck cancer radiotherapy patients: is high-risk, prolonged feeding tube use indicative of on-treatment weight loss? *Journal of Medical Radiation Sciences* 2019;66:250-8.
3. Banting S, Gyorki DE. ASO Author Reflections: The Impacts of a Negative Sentinel Lymph Node on Quality of Life. *Annals of Surgical Oncology* 2019;26:651-2.
4. Basto J, Chahal R, Riedel B. Time-driven activity-based costing to model the utility of parallel induction redesign in high-turnover operating lists. *Healthcare* 2019;7:100355.
5. Bawazeer O, Herath S, Sarasanandarajah S, Kron T, Dunn L, Deb P. A simple and efficient method to measure beam attenuation through a radiotherapy treatment couch and immobilization devices. *Australasian Physical and Engineering Sciences in Medicine* 2019;42:1183-9.
6. Bell S, Kong JC, Carne PWG, Chin M, Simpson P, Farmer C, Warriar SK. Oncological safety of laparoscopic versus open colorectal cancer surgery in obesity: a systematic review and meta-analysis. *ANZ Journal of Surgery* 2019;89:1549-55.
7. Briese M, Haberman N, Sibley CR, Faraway R, Elser AS, Chakrabarti AM, Wang Z, Konig J, Perera D, Wickramasinghe VO, Venkitaraman AR, Luscombe NM, Saieva L, Pellizzoni L, Smith CWJ, Curk T, Ule J. A systems view of spliceosomal assembly and branchpoints with iCLIP. *Nature Structural & Molecular Biology* 2019;26:930-40.
8. Burton A, Norvill C, Ebert MA. Predictive performance of an OVH-based treatment planning quality assurance model for prostate VMAT: Assessing dependence on training cohort size and composition. *Medical Dosimetry* 2019;44:315-23.
9. Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR. The clinical KRAS^{G12C} inhibitor AMG 510 drives anti-tumour immunity. *Nature* 2019;575:217-23.
10. Clarke M, Lewin J, Lazarakis S, Thompson K. Overlooked Minorities: The Intersection of Cancer in Lesbian, Gay, Bisexual, Transgender, and/or Intersex Adolescents and Young Adults. *Journal of Adolescent and Young Adult Oncology* 2019;8:525-8.
11. Curran D, Matthews S, Rowley SD, Young JH, Bastidas A, Anagnostopoulos A, Barista I, Chandrasekar PH, Dickinson M, El Idrissi M, Heras I, Milliken ST, Monserrat Coll J, Navarro Matilla MB, Oostvogels L, Piatkowska-Jakubas B, Quiel D, Sabry W, Schwartz S, Selleslag DLD, Sullivan KM, Theunissen K, Yegin

- ZA, Yeh SP, Zaja F, Szer J. Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). *Biology of Blood and Marrow Transplantation* 2019;25:2474-81.
12. Deng R, Gibiansky L, Lu T, Agarwal P, Ding H, Li X, Kshirsagar S, Lu D, Li C, Girish S, Wang J, Boyer M, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. *Clinical Pharmacokinetics* 2019;58:1621-34.
 13. Dobie G, Kuriri FA, Omar MMA, Alanazi F, Gazwani AM, Tang CPS, Sze DM, Handunnetti SM, Tam C, Jackson DE. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIIb-IX-V complex and integrin α IIb β 3 in mice and humans. *Blood Advances* 2019;3:4298-311.
 14. Douglas AP, Thursky KA, Worth LJ, Harrison SJ, Hicks RJ, Slavin MA. FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia. *Leukemia and Lymphoma* 2019;60:2471-6.
 15. Dowling MR, Ballen KK. Neurological Complications after Allogeneic Transplantation - Can We Do Better? *Acta Haematologica* 2019;142:193-4.
 16. Fendler WP, Weber M, Irvani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. *Clinical Cancer Research* 2019;25:7448-54.
 17. Gamell C, Bandilovska I, Gulati T, Kogan A, Lim SC, Kovacevic Z, Takano EA, Timpone C, Agupitan AD, Litchfield C, Blandino G, Horvath LG, Fox SB, Williams SG, Russo A, Gallo E, Paul PJ, Mitchell C, Sandhu S, Keam SP, Haupt S, Richardson DR, Haupt Y. E6AP Promotes a Metastatic Phenotype in Prostate Cancer. *iScience* 2019;22:1-15.
 18. Gelman H, Dines JN, Berg J, Berger AH, Brnich S, Hisama FM, James RG, Rubin AF, Shendure J, Shirts B, Fowler DM, Starita LM. Recommendations for the collection and use of multiplexed functional data for clinical variant interpretation. *Genome Medicine* 2019;11:85.
 19. Gontero P, Marra G, Alessio P, Filippini C, Oderda M, Munoz F, Linares E, Sanchez-Salas R, Challacombe B, Dasgupta P, Goonewardene S, Popert R, Cahill D, Gillatt D, Persad R, Palou J, Joniau S, Piechaud T, Morlacco A, Vidit S, Roupret M, De La Taille A, Albisinni S, Gandaglia G, Mottrie A, Joshi S, Fiscus G, Berger A, Aron M, Van Der Poel H, Tilki D, Lawrentschuk N, Murphy DG, Leung G, Davis J, Karnes RJ. Salvage Radical Prostatectomy for Recurrent Prostate Cancer: Morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches. *Journal of Urology* 2019;202:725-31.
 20. Grech LB, Butler E, Stuckey S, Hester R. Neuroprotective Benefits of Antidepressants in Multiple Sclerosis: Are We Missing the Mark? *Journal of Neuropsychiatry and Clinical Neurosciences* 2019;31:289-97.
 21. Guccione L, Gough K, Drosowsky A, Fisher K, Price T, Pavlakis N, Khasraw M, Wyld D, Ransom D, Kong G, Rogers M, Leyden S, Leyden J, Michael M, Schofield P. Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. *JMIR Research Protocols* 2019;8:e14361.
 22. Hochheiser K, Aw Yeang HX, Wagner T, Tutuka C, Behren A, Waithman J, Angel C, Neeson PJ, Gebhardt T, Gyorki DE. Accumulation of CD103⁺ CD8⁺ T cells in a cutaneous melanoma micrometastasis. *Clinical & Translational Immunology* 2019;8:e1100.
 23. Hofman MS, Emmett L, Violet J, A YZ, Lawrence NJ, Stockler M, Francis RJ, Irvani A, Williams S, Azad A, Martin A, McJannett M, Davis ID. TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic

treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603). *BJU International* 2019;124 Suppl 1:5-13.

24. Hu Y, Byrne M, Archibald-Heeren B, Thompson K, Fong A, Knesl M, Teh A, Tiong E, Foster R, Melnyk P, Burr M, Thompson A, Lim J, Moore L, Gordon F, Humble R, Hardy A, Williams S. Implementing user-defined atlas-based auto-segmentation for a large multi-centre organisation: the Australian Experience. *Journal of Medical Radiation Sciences* 2019;66:238-49.
25. Iravani A, Solomon B, Pattison DA, Jackson P, Ravi Kumar A, Kong G, Hofman MS, Akhurst T, Hicks RJ. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. *Thyroid* 2019;29:1634-45.
26. Jameson MB, Gormly K, Espinoza D, Hague W, Asghari G, Jeffery GM, Price TJ, Karapetis CS, Arendse M, Armstrong J, Childs J, Frizelle FA, Ngan S, Stevenson A, Oostendorp M, Ackland SP. SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial. *BMC Cancer* 2019;19:1229.
27. Kang Y, Anderson AJ, Jackson TD, Palmer CS, De Souza DP, Fujihara KM, Stait T, Frazier AE, Clemons NJ, Tull D, Thorburn DR, McConville MJ, Ryan MT, Stroud DA, Stojanovski D. Function of hTim8a in complex IV assembly in neuronal cells provides insight into pathomechanism underlying Mohr-Tranebjaerg syndrome. *Elife* 2019;8:e48828.
28. Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME, Wyatt AW, Chi KN. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. *Lancet Oncology* 2019;20:1730-9.
29. Kim RS, Song N, Gavin PG, Salgado R, Bandos H, Kos Z, Floris G, Eynden G, Badve S, Demaria S, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Costantino JP, Paik S, Wolmark N, Geyer CE, Lucas PC, Pogue-Geile KL. Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. *Journal of the National Cancer Institute* 2019;111:867-71.
30. Kiss-Lane T, Spruijt O, Day T, Lam V, Ramchandran KJ, Chan S, Hsin G, Vallath N, Bhatnagar S, Rajagopal MR, Lorenz KA. Palliative care clinicians and online education in India: a survey. *BMJ Supportive & Palliative Care* 2019;9:e35.
31. Le Nours J, Gherardin NA, Ramarathinam SH, Awad W, Wiede F, Gully BS, Khandokar Y, Praveena T, Wubben JM, Sandow JJ, Webb AI, von Borstel A, Rice MT, Redmond SJ, Seneviratna R, Sandoval-Romero ML, Li S, Souter MNT, Eckle SBG, Corbett AJ, Reid HH, Liu L, Fairlie DP, Giles EM, Westall GP, Tothill RW, Davey MS, Berry R, Tiganis T, McCluskey J, Pellicci DG, Purcell AW, Uldrich AP, Godfrey DI, Rossjohn J. A class of gammadelta T cell receptors recognize the underside of the antigen-presenting molecule MR1. *Science* 2019;366:1522-7.
32. Li N, McInerney S, Zethoven M, Cheasley D, Lim BWX, Rowley SM, Devereux L, Grewal N, Ahmadloo S, Byrne D, Lee JEA, Li J, Fox SB, John T, Antill Y, Gorringer KL, James PA, Campbell IG. Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer. *Journal of the National Cancer Institute* 2019;111:1332-8.
33. Loi S. The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine. *Annals of Oncology* 2019;30:1183-4.
34. Loi S. Around the world and back again. *Nature Medicine* 2019;25:1466.
35. Lorent J, Kusnadi EP, van Hoef V, Rebello RJ, Leibovitch M, Ristau J, Chen S, Lawrence MG, Szkop KJ, Samreen B, Balanathan P, Rapino F, Close P, Bukczynska P, Scharmann K, Takizawa I, Risbridger GP, Selth LA, Leidel SA, Lin Q, Topisirovic I, Larsson O, Furic L. Translational offsetting as a mode of estrogen receptor alpha-dependent regulation of gene expression. *EMBO Journal* 2019;38:e101323.

36. Lye J, Kry S, Shaw M, Gibbons F, Keehan S, Lehmann J, Kron T, Followill D, Williams I. A comparison of IROC and ACDS on-site audits of reference and non-reference dosimetry. *Medical Physics* 2019;46:5878-87.
37. MacKay Helou S, Gadberry C, Tran S, Zahara N, Talbot J, Vidhyarkorn T, Nickols C, Russell J, Otap D, Churchill S, Estrabaut M, Piggee J, Scher C. A relationship-based approach to improving clinical trials: The imCORE research network experience. *Contemporary Clinical Trials* 2019;86:105861.
38. Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Fruh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. *Annals of Oncology* 2019;30:1321-8.
39. Meher-Homji Z, Tam CS, Siderov J, Seymour JF, Holmes NE, Chua KYL, Phillips EJ, Slavin MA, Trubiano JA. High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing. *Leukemia and Lymphoma* 2019;60:3455-60.
40. Nederlof I, De Bortoli D, Bareche Y, Nguyen B, de Maaker M, Hooijer GKJ, Buisseret L, Kok M, Smid M, Van den Eynden G, Brinkman AB, Hudecek J, Koster J, Sotiriou C, Larsimont D, Martens JWM, van de Vijver MJ, Horlings HM, Salgado R, Biganzoli E, Desmedt C. Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. *Breast Cancer Research* 2019;21:151.
41. Ong CW, Chen SC, Clark JE, Halliday CL, Kidd SE, Marriott DJ, Marshall CL, Morris AJ, Morrissey CO, Roy R, Slavin MA, Stewardson AJ, Worth LJ, Heath CH. Diagnosis, management and prevention of *Candida auris* in hospitals: position statement of the Australasian Society for Infectious Diseases. *Internal Medicine Journal* 2019;49:1229-43.
42. Owen KL, Brockwell NK, Parker BS. JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression. *Cancers* 2019;11:2002.
43. Paige E, Haywood P, Xie M, Worth L, Thursky K, Urbancic K, Bajel A, Slavin M. Auditing fungal disease in leukemia patients in a tertiary care center: opportunities and challenges for an antifungal stewardship program. *Leukemia and Lymphoma* 2019;60:2373-83.
44. Park JH, Jonas SF, Bataillon G, Criscitiello C, Salgado R, Loi S, Viale G, Lee HJ, Dieci MV, Kim SB, Vincent-Salomon A, Curigliano G, Andre F, Michiels S. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. *Annals of Oncology* 2019;30:1941-9.
45. Qu LG, Lawrentschuk N. Orthotopic Neobladder Reconstruction: Patient Selection And Perspectives. *Research and Reports in Urology* 2019;11:333-41.
46. Sathianathen NJ, Alarid-Escudero F, Kuntz KM, Lawrentschuk N, Bolton DM, Murphy DG, Kim SP, Konety BR. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer. *European Urology Oncology* 2019;2:649-55.
47. Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. *Lancet Oncology* 2019;20:1691-701.
48. Sheppard DM, Frost D, Jefford M, O'Connor M, Halkett G. 'Beyond Cancer': a study protocol of a multimodal occupational rehabilitation programme to support breast cancer survivors to return work. *BMJ Open* 2019;9:e032505.
49. Sinclair M, Schofield P, Turner J, Rauch P, Wakefield C, Mann GB, Newman L, Mason K, Gilham L, Cannell J, Stafford L. Maternal breast cancer and communicating with children: A qualitative

exploration of what resources mothers want and what health professionals provide. *European Journal of Cancer Care* 2019;28:e13153.

50. Solomon B, Young RJ, Bressel M, Cernelc J, Savas P, Liu H, Urban D, Thai A, Cooper C, Fua T, Neeson P, Loi S, Porceddu SV, Rischin D. Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance. *Annals of Oncology* 2019;30:1638-46.
51. Suerink M, Rodriguez-Gironde M, van der Klift HM, Colas C, Brugieres L, Lavoine N, Jongmans M, Munar GC, Evans DG, Farrell MP, Genuardi M, Goldberg Y, Gomez-Garcia E, Heinimann K, Hoell JJ, Aretz S, Jaspersen KW, Kedar I, Modi MB, Nikolaev S, van Os TAM, Ripperger T, Rueda D, Senter L, Sjursen W, Sunde L, Therkildsen C, Tibiletti MG, Trainer AH, Vos YJ, Wagner A, Winship I, Wimmer K, Zimmermann SY, Vasen HF, van Asperen CJ, Houwing-Duistermaat JJ, Ten Broeke SW, Nielsen M. An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. *Genetics in Medicine* 2019;21:2706-12.
52. Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, Ravi Kumar A, Murphy DG, Williams SG, Hicks RJ, Hofman MS. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy. *European Urology Oncology* 2019;2:670-6.
53. Valentine JC, Hall L, Verspoor KM, Worth LJ. The current scope of healthcare-associated infection surveillance activities in hospitalized immunocompromised patients: a systematic review. *International Journal of Epidemiology* 2019;48:1768-82.
54. von Scheidt B, Wang M, Oliver AJ, Chan JD, Jana MK, Ali AI, Clow F, Fraser JD, Quinn KM, Darcy PK, Kershaw MH, Slaney CY. Enterotoxins can support CAR T cells against solid tumors. *Proceedings of the National Academy of Sciences of the United States of America* 2019;116:25229-35.
55. Webber K, Carolus E, Mileshkin L, Sommeijer D, McAlpine J, Bladgen S, Coleman RL, Herzog TJ, Sehouli J, Nasser S, Inci G, Friedlander M. OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. *Gynecologic Oncology* 2019;155:126-34.
56. Wight JC, Yue M, Keane C, Johnston A, Linton K, Chin C, Wai SH, Talaulikar D, Gasiorowski R, Cheah CY, Gregory GP, Dickinson M, Minson A, Coombes C, Ku M, Lam S, Hawkes EA. Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. *British Journal of Haematology* 2019;187:174-84.
57. Wong A, Billett A, Milne D. Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy? *Oncologist* 2019;24:e1190-6.